<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02164981</url>
  </required_header>
  <id_info>
    <org_study_id>2014P001204</org_study_id>
    <nct_id>NCT02164981</nct_id>
    <nct_alias>NCT02695589</nct_alias>
  </id_info>
  <brief_title>A Proof of Concept Study of Intravenous Sodium Nitroprusside in Adults With Symptomatic Schizophrenia</brief_title>
  <official_title>A Randomized Double-Blind, Placebo-Controlled, Proof of Concept Study of Intravenous Sodium Nitroprusside in Adults With Symptomatic Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanley Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to investigate whether a single infusion of
      intravenous sodium nitroprusside (0.5 μg/kg/min for 4 hours) is superior to placebo (5%
      dextrose solution) at in treating positive and negative symptoms of schizophrenia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II proof of concept (POC), multi-center, prospective, randomized,
      placebo-controlled, Sequential Parallel Comparison Design (SPCD) study, in which a total of
      60 subjects with schizophrenia will be enrolled.

      The study will be conducted in two stages. The study treatment will be administered in a
      double-blind fashion for all subjects throughout both stages of the study. A total of 60
      subjects with schizophrenia will be randomized in a 1:1:1 ratio to drug-drug sequence [n=20;
      i.v. sodium nitroprusside (0.5 μg/kg/min for 4 hours) at week 0 and week 2], placebo-drug
      sequence [n=20; i.v. placebo at week 0 and i.v. sodium nitroprusside (0.5 μg/kg/min for 4
      hours) at week 2], and placebo-placebo sequence [n=20; i.v. placebo at week 0 and again at
      week 2]. The 4-week double-blind phase of treatment will be divided into two phases: Phase 1,
      from week 0 to week 2, and Phase 2 from week 2 to week 4. At the end of Phase 1 (week 2), the
      randomized subjects will be assessed and categorized into responders and non-responders,
      based on 20% or more reduction from baseline in their PANSS total score as per the
      evaluations at Randomization Visit (week 0). The data from the patients deemed placebo
      non-responders in phase 1 who go on to either stay on placebo or to receive treatment with
      sodium nitroprusside will be pooled with the data from Phase 1 from all subjects, according
      to SPCD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 1, 2015</start_date>
  <completion_date type="Actual">April 5, 2017</completion_date>
  <primary_completion_date type="Actual">March 31, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Positive and Negative Syndrome Scale (PANSS) - Total Score - Study Phases 1 and 2</measure>
    <time_frame>For Phase 1, timeframe is Day 0 and Day 14; Phase 2 timeframe is Day 14 and Day 28</time_frame>
    <description>The Positive and Negative Syndrome Scale (PANSS) will be used to measure symptom severity in this trial. PANSS is a 30-item questionnaire used to evaluate schizophrenia symptoms, based on the clinical interview as well as reports of family members or primary care hospital workers. PANSS consists of Positive scale (7 items), Negative scale (7 items), and General Psychopathological scale (16 items) sections. Each item (symptom) will be scored on a 7-point scale with higher scores representing increasing levels of psychopathology: 1) Absent, 2) Minimal, 3) Mild, 4) Moderate, 5) Moderate severe, 6) Severe, and 7) Extreme. Total score minimum = 30, maximum = 210</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PANSS - Positive Subscale - Phases 1 and 2</measure>
    <time_frame>Phase 1 timeframe is Baseline and Day 14; Phase 2 timeframe is Day 14 and Day 28</time_frame>
    <description>The Positive and Negative Syndrome Scale (PANSS) will be used to measure symptom severity in this trial. PANSS is a 30-item questionnaire used to evaluate schizophrenia symptoms, based on the clinical interview as well as reports of family members or primary care hospital workers. PANSS consists of Positive scale (7 items), Negative scale (7 items), and General Psychopathological scale (16 items) sections. Each item (symptom) will be scored on a 7-point scale with higher scores representing increasing levels of psychopathology: 1) Absent, 2) Minimal, 3) Mild, 4) Moderate, 5) Moderate severe, 6) Severe, and 7) Extreme. Positive scale: 7 Items, (minimum score = 7, maximum score = 49)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PANSS - Negative Subscale - Phases 1 and 2</measure>
    <time_frame>Phase 1 timeframe is Day 0 and Day 14; Phase 2 timeframe is Day 14 and Day 28</time_frame>
    <description>The Positive and Negative Syndrome Scale (PANSS) will be used to measure symptom severity in this trial. PANSS is a 30-item questionnaire used to evaluate schizophrenia symptoms, based on the clinical interview as well as reports of family members or primary care hospital workers. PANSS consists of Positive scale (7 items), Negative scale (7 items), and General Psychopathological scale (16 items) sections. Each item (symptom) will be scored on a 7-point scale with higher scores representing increasing levels of psychopathology: 1) Absent, 2) Minimal, 3) Mild, 4) Moderate, 5) Moderate severe, 6) Severe, and 7) Extreme. Negative scale: 7 Items, (minimum score = 7, maximum score = 49)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PANSS - General Psychopathology Subscale - Phases 1 and 2</measure>
    <time_frame>Phase 1 timeframe is Baseline and Day 14; Phase 2 timeframe is Day 14 and Day 28</time_frame>
    <description>The Positive and Negative Syndrome Scale (PANSS) will be used to measure symptom severity in this trial. PANSS is a 30-item questionnaire used to evaluate schizophrenia symptoms, based on the clinical interview as well as reports of family members or primary care hospital workers. PANSS consists of Positive scale (7 items), Negative scale (7 items), and General Psychopathological scale (16 items) sections. Each item (symptom) will be scored on a 7-point scale with higher scores representing increasing levels of psychopathology: 1) Absent, 2) Minimal, 3) Mild, 4) Moderate, 5) Moderate severe, 6) Severe, and 7) Extreme. General Psychopathology Subscale: 16 Items, (minimum score = 16, maximum score = 112)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Percent Change From Baseline in the PANSS Total Score After 2 Weeks of Treatment Using SPCD</measure>
    <time_frame>For Phase 1, timeframe is Baseline and Day 14; Phase 2 timeframe is Day 14 and Day 28</time_frame>
    <description>The Positive and Negative Syndrome Scale (PANSS) will be used to measure symptom severity in this trial. PANSS is a 30-item questionnaire used to evaluate schizophrenia symptoms, based on the clinical interview as well as reports of family members or primary care hospital workers. PANSS consists of Positive scale (7 items), Negative scale (7 items), and General Psychopathological scale (16 items) sections. Each item (symptom) will be scored on a 7-point scale with higher scores representing increasing levels of psychopathology: 1) Absent, 2) Minimal, 3) Mild, 4) Moderate, 5) Moderate severe, 6) Severe, and 7) Extreme. Total score minimum = 30, maximum = 210.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With 20% or More Reduction From Baseline in PANSS Total Score After 2 Weeks of Treatment Using SPCD</measure>
    <time_frame>For Phase 1, timeframe is Baseline and Day 14; Phase 2 timeframe is Day 14 and Day 28</time_frame>
    <description>The Positive and Negative Syndrome Scale (PANSS) will be used to measure symptom severity in this trial. PANSS is a 30-item questionnaire used to evaluate schizophrenia symptoms, based on the clinical interview as well as reports of family members or primary care hospital workers. PANSS consists of Positive scale (7 items), Negative scale (7 items), and General Psychopathological scale (16 items) sections. Each item (symptom) will be scored on a 7-point scale with higher scores representing increasing levels of psychopathology: 1) Absent, 2) Minimal, 3) Mild, 4) Moderate, 5) Moderate severe, 6) Severe, and 7) Extreme. Total score minimum = 30, maximum = 210.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Percent Change From Baseline in the PANSS Positive Subscale Score After 2 Weeks of Treatment Using SPCD</measure>
    <time_frame>For Phase 1, timeframe is Baseline and Day 14; Phase 2 timeframe is Day 14 and Day 28</time_frame>
    <description>The Positive and Negative Syndrome Scale (PANSS) will be used to measure symptom severity in this trial. PANSS is a 30-item questionnaire used to evaluate schizophrenia symptoms, based on the clinical interview as well as reports of family members or primary care hospital workers. PANSS consists of Positive scale (7 items), Negative scale (7 items), and General Psychopathological scale (16 items) sections. Each item (symptom) will be scored on a 7-point scale with higher scores representing increasing levels of psychopathology: 1) Absent, 2) Minimal, 3) Mild, 4) Moderate, 5) Moderate severe, 6) Severe, and 7) Extreme. Positive subscore scale: 7 items (minimum score = 7; maximum score = 49)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Percent Change From Baseline in the PANSS Negative Subscale Score After 2 Weeks of Treatment Using SPCD</measure>
    <time_frame>For Phase 1, timeframe is Baseline and Day 14; Phase 2 timeframe is Day 14 and Day 28</time_frame>
    <description>The Positive and Negative Syndrome Scale (PANSS) will be used to measure symptom severity in this trial. PANSS is a 30-item questionnaire used to evaluate schizophrenia symptoms, based on the clinical interview as well as reports of family members or primary care hospital workers. PANSS consists of Positive scale (7 items), Negative scale (7 items), and General Psychopathological scale (16 items) sections. Each item (symptom) will be scored on a 7-point scale with higher scores representing increasing levels of psychopathology: 1) Absent, 2) Minimal, 3) Mild, 4) Moderate, 5) Moderate severe, 6) Severe, and 7) Extreme. Negative subscore scale: 7 items (minimum score = 7; maximum score = 49)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Percent Change From Baseline in the PANSS General Psychopathology Subscale Score After 2 Weeks of Treatment Using SPCD</measure>
    <time_frame>For Phase 1, timeframe is Baseline and Day 14; Phase 2 timeframe is Day 14 and Day 28</time_frame>
    <description>The Positive and Negative Syndrome Scale (PANSS) will be used to measure symptom severity in this trial. PANSS is a 30-item questionnaire used to evaluate schizophrenia symptoms, based on the clinical interview as well as reports of family members or primary care hospital workers. PANSS consists of Positive scale (7 items), Negative scale (7 items), and General Psychopathological scale (16 items) sections. Each item (symptom) will be scored on a 7-point scale with higher scores representing increasing levels of psychopathology: 1) Absent, 2) Minimal, 3) Mild, 4) Moderate, 5) Moderate severe, 6) Severe, and 7) Extreme. General Psychopathology subscore scale: 16 items (minimum score = 16; maximum score = 112)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) - Phases 1 and 2</measure>
    <time_frame>Phase 1 timeframe is Baseline and Day 14; Phase 2 timeframe is Day 14 and Day 28</time_frame>
    <description>MATRICS: The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB). The MATRICS Consensus Cognitive Battery is the standard tool for assessing cognitive change in trials of cognitive-enhancing agents in schizophrenia. The MCCB domains include: Speed of Processing; Attention/Vigilance; Working Memory; Verbal Learning; Visual Learning; Reasoning &amp; Problem-Solving; and Social Cognition and the battery takes about 80 minutes to complete. The MCCB composite score represents a global measure of cognition. MCCB composite T scores are between 40 and 60 (normal range) and &lt; 40 (below normal range).</description>
  </other_outcome>
  <other_outcome>
    <measure>Average AIMS Total Scores (Items 1-7) by Group and Timepoint</measure>
    <time_frame>Baseline 1 (Day -1), 7 Hours Post-Infusion 1, Baseline 2 (Day 13), 7 Hours Post-Infusion 2, Final Follow-Up, including early termination visits</time_frame>
    <description>Abnormal Involuntary Movement Scale (AIMS):
The AIMS Total Dyskinesia Score was calculated by averaging the first 7 items of the AIMS. The 7 items included in the AIMS Dyskinesia Score are rated on a scale from 0 (no dyskinesia) to 4 (severe dyskinesia). Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). The AIMS dyskinesia total score ranges from 0 to 4; a higher score reflects increased severity.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent of Participants Rated as ≥ &quot;Mild&quot; or as &quot;Yes&quot; on AIMS Items 8-12</measure>
    <time_frame>Baseline (Day -1), Follow-Up = reported at any assessment thereafter, including 7 hours after Infusions #1 and #2, Baseline 2 (Day 13) and final follow-up, including early termination visits.</time_frame>
    <description>Abnormal Involuntary Movement Scale (AIMS):
The AIMS is a 12-item anchored score that is clinician administered and scored. Items are scored on a 0 (none) to 4 (severe) basis; items 8-10 deal with global severity; items 11-12 are yes-no questions concerning problems with teeth and/or dentures.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in The University of California San Diego (UCSD) Performance-based Skills Assessment Brief (UPSA-B) - Phases 1 and 2</measure>
    <time_frame>Phase 1 timeframe is Baseline and Day 14; Phase 2 timeframe is Day 14 and Day 28</time_frame>
    <description>The University of California San Diego (UCSD) Performance-based Skills Assessment Brief (UPSA-B) consists of two of the five original UPSA domains, finances and communication. Each subscale contributes 50 points; total scores range from 0 to 100 points with higher scores reflecting better performance.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants Reporting Suicidal Ideation/Behavior on the Columbia Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>Screening Visit, Days 3 (Baseline 1), Days 7, 13 (Baseline 2), 21 and 28</time_frame>
    <description>The Columbia Suicide Severity Rating Scale (C-SSRS): The C-SSRS is a low-burden measure of the spectrum of suicidal ideation and behavior that was developed in the National Institute of Mental Health Treatment of Adolescent Suicide Attempters Study to assess severity and track suicidal events through any treatment. It is a clinical interview providing a summary of both ideation and behavior that can be administered during any evaluation or risk assessment to identify the level and type of suicidality present. The C-SSRS can also be used during treatment to monitor for clinical worsening or improvement. It contains 5 rating scale questions (yes/no) for suicidal ideation increasing severity and 5 rating scale questions (yes/no) for suicidal behavior of increasing severity. The time frame is for both lifetime and the past six months for the Baseline/Screening scale and since the last visit for the Since Last Visit scale.</description>
  </other_outcome>
  <other_outcome>
    <measure>Systolic Blood Pressure Per Infusion Phase by Group</measure>
    <time_frame>Day 0 - Phase 1 - Baseline = min000s1 and @5 min; Phase 2 - Baseline = min000 then every 10 minutes for 4 hours; Post Infusion - Baseline = min000, then every 10 minutes for 2 hours</time_frame>
    <description>Infusion 1 (Day 0) - Systolic Blood Pressure at all time points by group
&quot;Phase&quot; in this analysis refers to the infusion stage as defined in the protocol.</description>
  </other_outcome>
  <other_outcome>
    <measure>Diastolic Blood Pressure Per Infusion Phase by Group</measure>
    <time_frame>Day 0 - Phase 1 - Baseline = min000s1 and @5 min; Phase 2 - Baseline = min000 then every 10 minutes for 4 hours; Post Infusion - Baseline = min000, then every 10 minutes for 2 hours</time_frame>
    <description>Infusion 1 (Day 0) - Diastolic Blood Pressure at all time points by group
&quot;Phase&quot; in this analysis refers to the infusion stage as defined in the protocol.</description>
  </other_outcome>
  <other_outcome>
    <measure>Systolic Blood Pressure Per Infusion Phase by Group</measure>
    <time_frame>Day 14 - Phase 1 - Baseline = min000s1 and @5 min; Phase 2 - Baseline = min000 then every 10 minutes for 4 hours; Post Infusion - Baseline = min000, then every 10 minutes for 2 hours</time_frame>
    <description>Infusion 2 (Day 14) - Systolic Blood Pressure at all time points by group
&quot;Phase&quot; in this analysis refers to the infusion stage as defined in the protocol.</description>
  </other_outcome>
  <other_outcome>
    <measure>Phase 2 - Diastolic Blood Pressure Per Infusion Phase by Group</measure>
    <time_frame>Day 14 - Phase 1 - Baseline = min000s1 and @5 min; Phase 2 - Baseline = min000 then every 10 minutes for 4 hours; Post Infusion - Baseline = min000, then every 10 minutes for 2 hours</time_frame>
    <description>Infusion 2 (Day 14) - Diastolic Blood Pressure at all time points by group</description>
  </other_outcome>
  <other_outcome>
    <measure>Heart Rate Per Infusion Phase by Group</measure>
    <time_frame>Day 0 - Phase 1 - Baseline = min000s1 and @5 min; Phase 2 - Baseline = min000 then every 10 minutes for 4 hours; Post Infusion - Baseline = min000, then every 10 minutes for 2 hours</time_frame>
    <description>Infusion 1 (Day 0) - Heart rate at all time points by group
&quot;Phase&quot; in this analysis refers to the infusion stage as defined in the protocol.</description>
  </other_outcome>
  <other_outcome>
    <measure>Heart Rate Per Infusion Phase by Group</measure>
    <time_frame>Day 14 - Phase 1 - Baseline = min000s1 and @5 min; Phase 2 - Baseline = min000 then every 10 minutes for 4 hours; Post Infusion - Baseline = min000, then every 10 minutes for 2 hours</time_frame>
    <description>Infusion 2 (Day 14) - Heart rate at all time points by group
&quot;Phase&quot; in this analysis refers to the infusion stage as defined in the protocol.</description>
  </other_outcome>
  <other_outcome>
    <measure>ECG Measures at All Time Points by Group</measure>
    <time_frame>Day 0 - Baseline (pre-infusion), During Infusion (@30 min), Post-Infusion (@60min)</time_frame>
    <description>Infusion 1 (Day 0) - ECG measures at all time points by group</description>
  </other_outcome>
  <other_outcome>
    <measure>ECG Measures at All Time Points by Group</measure>
    <time_frame>Day 14 - Baseline (pre-infusion), During Infusion (@30 min), Post-Infusion (@60min)</time_frame>
    <description>Infusion 2 (Day 14) - ECG measures at all time points by group</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>The period of observation for collection of treatment-emergent adverse events extends from Day 0 treatment through the final visit at Day 28.</time_frame>
    <description>Incidence of Treatment-Emergent Adverse Events (TEAE) by Treatment Group. A treatment emergent adverse event (TEAE) is an AE that either began following initiation of study treatment or was present prior to the initiation of the treatment, but increased in frequency or severity following initiation treatment, regardless of causality.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Subject Withdrawals Due to Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>The period of observation extends from Day 0 treatment through the final visit at Day 28</time_frame>
    <description>Incidence of Treatment-Emergent Adverse Events (TEAE) by Treatment Group. A treatment emergent adverse event (TEAE) is an AE that either began following initiation of study treatment or was present prior to the initiation of the treatment, but increased in frequency or severity following initiation treatment, regardless of causality.</description>
  </other_outcome>
  <other_outcome>
    <measure>Systematic Assessment for Treatment Emergent Effects-Systematic Inquiry (SAFTEE-SI) - Percent of Participants Reporting Experiencing Symptoms at &quot;Moderate&quot; or &quot;Severe&quot; Level for the 10 Most Frequently Reported Symptoms Post Randomization</measure>
    <time_frame>Baseline (Day - 1), Follow-Up = reported at any assessment thereafter, including 7 hours after Infusions #1 and #2, Baseline 2 (Day 13) and final follow-up, including early termination visits.</time_frame>
    <description>The Systematic Assessment for Treatment Emergent Effects-Systematic Inquiry (SAFTEE-SI): This is a self-rated 77-item questionnaire organized into 13 body areas assessing possible adverse events during the course of the trial.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Drug - Drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Phase 1 - intravenous sodium nitroprusside Phase 2 - intravenous sodium nitroprusside</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Drug</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Phase 1 - intravenous dextrose Phase 2 - intravenous sodium nitroprusside</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Phase 1 - intravenous dextrose Phase 2 - intravenous dextrose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium nitroprusside</intervention_name>
    <description>intravenous</description>
    <arm_group_label>Drug - Drug</arm_group_label>
    <arm_group_label>Placebo - Drug</arm_group_label>
    <other_name>Nitropress</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo - Placebo</arm_group_label>
    <other_name>5% dextrose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Each subject must meet all of the following criteria to be eligible for this study:

          1. Males or Females aged 18-65 years inclusive.

          2. Primary diagnosis of Schizophrenia established by a structured psychiatric evaluation
             (SCID) based on Diagnostic and Statistical Manual of Mental Disorders Forth Edition
             (DSM-IV-TR) criteria.

          3. Written informed consent in compliance with 21 CFR part 50 and in accordance with the
             International Conference on Harmonization (ICH) Good Clinical Practice (GCP)
             Guidelines.

          4. A Positive and Negative Syndrome Scale (PANSS) (Kay et al., 1994) total score ≥ 70
             with a score of &gt; 4 on two or more of the following PANSS items: delusions, conceptual
             disorganization, hallucinatory behavior, suspiciousness, and unusual thought content.

          5. A score of ≥4 on the Clinical Global Impression—Severity (CGI-S) (Guy, 1976).

          6. Confirmation of both diagnosis and severity of psychosis symptoms by an independent
             MGH SAFER interview.

          7. Must have ongoing antipsychotic treatment for at least 8 weeks, with a stable dose for
             at least 4 weeks. Subjects who have failed to achieve clinically-recognized symptom
             reduction to at least 1 marketed antipsychotic agent, given at a Physician Desk
             Reference (PDR)-defined therapeutic dose for ≥ 8 weeks during the past 12 months, as
             assessed by the MGH FAST, will be eligible

          8. Understands and is able, willing, and (in the opinion of the investigator) likely to
             fully comply with the study procedures and restrictions.

        Exclusion Criteria

        Subjects who meet any of the following criteria will be excluded from the study:

          1. Subjects with a history of renal insufficiency, congestive heart failure, cardiac
             arrhythmias or history of myocardial infarction.

          2. Subjects with a history of symptomatic orthostatic hypotension defined as sitting to
             standing systolic blood pressure &lt; 90mmHg or diastolic blood pressure &lt; 60mm Hg with
             any of the following symptoms: lightheaded or dizzy upon standing, blurry vision,
             weakness, fainting (syncope), confusion, or nausea.

          3. Subjects with any clinically significant abnormalities as determined by medical
             history, physical exam, clinical and lab evaluation suggestive of an underlying
             disease state that may, in the opinion of the investigator, confound the results of
             study, increase risk to the subject, or lead to difficulty complying with the
             protocol.

          4. Subjects on chlorpromazine, PDE-5 inhibitors, nitrites and any medication with CNS
             effects with the exception of antipsychotic drugs (other than chlorpromazine)
             anticholinergics, b-adrenergic antagonists, amantadine, biperiden, diphenhydramine,
             lorazepam, zolpidem, and temazepam.

          5. Medications which in the opinion of the PI, and in conjunction with the medical
             monitor, may be expected to significantly interfere with the metabolism or excretion
             of sodium nitroprusside, and/or may be associated with a significant drug interaction
             with sodium nitroprusside that may pose a significant risk to subjects' health and/or
             confound the study data.

          6. Pregnant or breast-feeding patients. Women of childbearing potential must have a
             negative pregnancy test performed at screening visit prior to randomization and prior
             to baseline at visits 3 and 6. Women enrolled in this trial must use adequate birth
             control.

          7. Subjects with a current (within the last 3 months) DSM-IV-TR diagnosis of alcohol or
             substance use disorder or dependence (excluding nicotine) as established by the
             clinical assessment (SCID) at the screening visit will be excluded.

          8. Has tested positive for any of the following: cannabis, opioids, cocaine,
             amphetamines, barbiturates methadone, methamphetamine and phencyclidine at the
             screening or baseline visits. If positive, the urine drug toxicology screen may be
             repeated once based on investigator judgment, but due to safety concerns, the result
             must be negative for the subject to continue in the study.

          9. Subjects at imminent risk of suicide or injury to self or others, as per the opinion
             of the investigator, or history of significant suicide attempt within the last 6
             months as per C-SSRS.

         10. Subjects that have taken an investigational drug or taken part in a clinical trial
             within 30 days prior to screening.

         11. Any other reason that, in the opinion of the investigator, would compromise patient
             safety or integrity of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maurizio Fava, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roy Perlis, MD MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Schizophrenia Clinical Research Program, Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zucker Hillside Hospital</name>
      <address>
        <city>Glen Oaks</city>
        <state>New York</state>
        <zip>11004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University Langone Medical Center/Bellevue Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>June 13, 2014</study_first_submitted>
  <study_first_submitted_qc>June 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2014</study_first_posted>
  <results_first_submitted>March 30, 2018</results_first_submitted>
  <results_first_submitted_qc>September 4, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 2, 2018</results_first_posted>
  <last_update_submitted>September 4, 2018</last_update_submitted>
  <last_update_submitted_qc>September 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Maurizio Fava, MD</investigator_full_name>
    <investigator_title>Director, Clinical Research Program</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitroprusside</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 1, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT02164981/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 1, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT02164981/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Per the Sequential Parallel Comparison Design, the 18 subjects in the SNP-SNP group were excluded from Phase 2 analyses. There were no Phase 1 placebo responders, so no exclusions were made based on this SPCD criterion. Ph 1 (N=52): all groups; Ph 2 (N=34): (Placebo)-Placebo (N=18), (SNP)-Placebo (N=16). All subjects were followed for 28 days.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Drug - Drug</title>
          <description>Phase 1 - intravenous sodium Nitroprusside (Drug) Phase 2 - intravenous sodium Nitroprusside (Drug)
Subjects will receive i.v. sodium nitroprusside (0.5 μg/kg/min for 4 hours) at Day 0 (Phase 1) and Day 14 (Phase 2)</description>
        </group>
        <group group_id="P2">
          <title>Placebo - Drug</title>
          <description>Phase 1 - intravenous dextrose (Placebo) Phase 2 - intravenous sodium Nitroprusside (Drug)
Subjects will receive i.v. placebo (intravenous dextrose) at Day 0 (Phase 1) and i.v. sodium nitroprusside (0.5 μg/kg/min for 4 hours) at Day 14 (Phase 2)</description>
        </group>
        <group group_id="P3">
          <title>Placebo - Placebo</title>
          <description>Phase 1 - intravenous dextrose (Placebo) Phase 2 - intravenous dextrose (Placebo)
Subjects will receive i.v. placebo (intravenous dextrose) at Day 0 (Phase 1) and again at Day 14 (Phase 2).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Started</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Phase 1 (Day 0 - Day 14)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Phase 2 (Day 14 - Day 28)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Drug - Drug</title>
          <description>Phase 1 - intravenous sodium Nitroprusside (Drug) Phase 2 - intravenous sodium Nitroprusside (Drug)
Subjects will receive i.v. sodium nitroprusside (0.5 μg/kg/min for 4 hours) at Day 0 (Phase 1) and Day 14 (Phase 2)</description>
        </group>
        <group group_id="B2">
          <title>Placebo - Drug</title>
          <description>Phase 1 - intravenous dextrose (Placebo) Phase 2 - intravenous sodium Nitroprusside (Drug)
Subjects will receive i.v. placebo (intravenous dextrose) at Day 0 (Phase 1) and i.v. sodium nitroprusside (0.5 μg/kg/min for 4 hours) at Day 14 (Phase 2)</description>
        </group>
        <group group_id="B3">
          <title>Placebo - Placebo</title>
          <description>Phase 1 - intravenous dextrose (Placebo) Phase 2 - intravenous dextrose (Placebo)
Subjects will receive i.v. placebo (intravenous dextrose) at Day 0 (Phase 1) and again at Day 14 (Phase 2).</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="18"/>
            <count group_id="B4" value="52"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.1" spread="10.5"/>
                    <measurement group_id="B2" value="45.9" spread="12.3"/>
                    <measurement group_id="B3" value="40.4" spread="11.0"/>
                    <measurement group_id="B4" value="44.5" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>The Positive and Negative Syndrome Scale (PANSS) at Baseline (Day 3)</title>
          <description>The Positive and Negative Syndrome Scale (PANSS) is a 30-item questionnaire used to evaluate schizophrenia symptoms; consisting of Positive (7 items), Negative (7 items), and General Psychopathological scales (16 items) sections. Each item (symptom) is scored on a 7-point scale, higher scores representing increasing levels of psychopathology: Positive scale: 7 Items, (min. score = 7, max. score = 49); Negative scale: 7 Items, (min. score = 7, max. score = 49). For this measure, only the positive and negative scales are included in the total score (min. total score = 14, max., score = 98)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>PANSS -total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83.6" spread="10.0"/>
                    <measurement group_id="B2" value="77.6" spread="8.8"/>
                    <measurement group_id="B3" value="81.7" spread="8.8"/>
                    <measurement group_id="B4" value="80.9" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PANSS - positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.9" spread="3.5"/>
                    <measurement group_id="B2" value="22.3" spread="3.4"/>
                    <measurement group_id="B3" value="22.6" spread="3.1"/>
                    <measurement group_id="B4" value="23.26" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PANSS - negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.9" spread="5.5"/>
                    <measurement group_id="B2" value="20.3" spread="5.0"/>
                    <measurement group_id="B3" value="21.4" spread="4.6"/>
                    <measurement group_id="B4" value="20.8" spread="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Positive and Negative Syndrome Scale (PANSS) - Total Score - Study Phases 1 and 2</title>
        <description>The Positive and Negative Syndrome Scale (PANSS) will be used to measure symptom severity in this trial. PANSS is a 30-item questionnaire used to evaluate schizophrenia symptoms, based on the clinical interview as well as reports of family members or primary care hospital workers. PANSS consists of Positive scale (7 items), Negative scale (7 items), and General Psychopathological scale (16 items) sections. Each item (symptom) will be scored on a 7-point scale with higher scores representing increasing levels of psychopathology: 1) Absent, 2) Minimal, 3) Mild, 4) Moderate, 5) Moderate severe, 6) Severe, and 7) Extreme. Total score minimum = 30, maximum = 210</description>
        <time_frame>For Phase 1, timeframe is Day 0 and Day 14; Phase 2 timeframe is Day 14 and Day 28</time_frame>
        <population>Ph 1 analysis includes 34 subjects with Baseline PANSS data in the Placebo-Placebo (N=18) and Placebo-Drug (N=16) groups and 18 Drug-Drug group subjects. Per SPCD, the Ph 2 data excludes 18 Drug-Drug group subjects and includes the 14 subjects in the Placebo-Drug group and 18 subjects in the Placebo-Placebo group with PANSS Baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Drug</title>
            <description>Phase 1 - intravenous sodium nitroprusside Phase 2 - intravenous sodium nitroprusside
sodium nitroprusside: intravenous</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Phase 1 - intravenous dextrose Phase 2 - intravenous dextrose
Placebo:</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Positive and Negative Syndrome Scale (PANSS) - Total Score - Study Phases 1 and 2</title>
          <description>The Positive and Negative Syndrome Scale (PANSS) will be used to measure symptom severity in this trial. PANSS is a 30-item questionnaire used to evaluate schizophrenia symptoms, based on the clinical interview as well as reports of family members or primary care hospital workers. PANSS consists of Positive scale (7 items), Negative scale (7 items), and General Psychopathological scale (16 items) sections. Each item (symptom) will be scored on a 7-point scale with higher scores representing increasing levels of psychopathology: 1) Absent, 2) Minimal, 3) Mild, 4) Moderate, 5) Moderate severe, 6) Severe, and 7) Extreme. Total score minimum = 30, maximum = 210</description>
          <population>Ph 1 analysis includes 34 subjects with Baseline PANSS data in the Placebo-Placebo (N=18) and Placebo-Drug (N=16) groups and 18 Drug-Drug group subjects. Per SPCD, the Ph 2 data excludes 18 Drug-Drug group subjects and includes the 14 subjects in the Placebo-Drug group and 18 subjects in the Placebo-Placebo group with PANSS Baseline data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phase 1 - Total Score - Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.6" spread="10.0"/>
                    <measurement group_id="O2" value="79.8" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 1 - Total Score - Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.6" spread="12.2"/>
                    <measurement group_id="O2" value="76.7" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 1 - Total Score - Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.0" spread="11.3"/>
                    <measurement group_id="O2" value="-2.5" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - Total Score - Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.0" spread="12.0"/>
                    <measurement group_id="O2" value="78.8" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - Total Score - Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.8" spread="10.6"/>
                    <measurement group_id="O2" value="74.7" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - Total Score - Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="8.2"/>
                    <measurement group_id="O2" value="-4.2" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Given the sequential parallel comparison design (SPCD), we used a two-stage test (weighted z-test, Tamura approach: CHANGE_score = BASELINE_value + GROUP (i.e., SNP vs. placebo)) to combine the data on treatment effects from phases 1 and 2 (weighted equally). Assessments were on Day -1 (phase 1 baseline), Day 13 (phase 1 outcome, phase 2 baseline) and Day 28 (phase 2 outcome). Only participants who at least started the infusion were included in analysis (i.e., modified intent to treat).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.57</p_value>
            <p_value_desc>No adjustment for multiple comparisons, as there was only one primary outcome variable.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.04</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The same analysis as in Analysis 1 was conducted, except that CLOZAPINE (i.e., patient used clozapine vs. other antipsychotic) was added as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.54</p_value>
            <p_value_desc>No adjustment for multiple comparisons, as there was only one primary outcome variable.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.09</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PANSS - Positive Subscale - Phases 1 and 2</title>
        <description>The Positive and Negative Syndrome Scale (PANSS) will be used to measure symptom severity in this trial. PANSS is a 30-item questionnaire used to evaluate schizophrenia symptoms, based on the clinical interview as well as reports of family members or primary care hospital workers. PANSS consists of Positive scale (7 items), Negative scale (7 items), and General Psychopathological scale (16 items) sections. Each item (symptom) will be scored on a 7-point scale with higher scores representing increasing levels of psychopathology: 1) Absent, 2) Minimal, 3) Mild, 4) Moderate, 5) Moderate severe, 6) Severe, and 7) Extreme. Positive scale: 7 Items, (minimum score = 7, maximum score = 49)</description>
        <time_frame>Phase 1 timeframe is Baseline and Day 14; Phase 2 timeframe is Day 14 and Day 28</time_frame>
        <population>Ph 1 analysis includes the 34 subjects with Baseline PANSS data in the Placebo-Placebo (N=18) and Placebo-Drug (N=16) groups and 22 Drug-Drug group subjects. Per SPCD, the Ph 2 data excludes the 18 Drug-Drug group subjects and includes the 14 subjects in the Placebo-Drug group and 18 subjects in the Placebo-Placebo group with PANSS Baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Drug</title>
            <description>Phase 1 - intravenous sodium Nitroprusside or placebo Phase 2 - intravenous sodium nitroprusside
sodium nitroprusside: intravenous</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Phase 1 - intravenous dextrose Phase 2 - intravenous dextrose
Placebo:</description>
          </group>
        </group_list>
        <measure>
          <title>PANSS - Positive Subscale - Phases 1 and 2</title>
          <description>The Positive and Negative Syndrome Scale (PANSS) will be used to measure symptom severity in this trial. PANSS is a 30-item questionnaire used to evaluate schizophrenia symptoms, based on the clinical interview as well as reports of family members or primary care hospital workers. PANSS consists of Positive scale (7 items), Negative scale (7 items), and General Psychopathological scale (16 items) sections. Each item (symptom) will be scored on a 7-point scale with higher scores representing increasing levels of psychopathology: 1) Absent, 2) Minimal, 3) Mild, 4) Moderate, 5) Moderate severe, 6) Severe, and 7) Extreme. Positive scale: 7 Items, (minimum score = 7, maximum score = 49)</description>
          <population>Ph 1 analysis includes the 34 subjects with Baseline PANSS data in the Placebo-Placebo (N=18) and Placebo-Drug (N=16) groups and 22 Drug-Drug group subjects. Per SPCD, the Ph 2 data excludes the 18 Drug-Drug group subjects and includes the 14 subjects in the Placebo-Drug group and 18 subjects in the Placebo-Placebo group with PANSS Baseline data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phase 1 - Positive Score - Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5" spread="3.5"/>
                    <measurement group_id="O2" value="22.3" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 1 - Positive Score - Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.1" spread="4.6"/>
                    <measurement group_id="O2" value="21.3" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 1 - Positive Score - Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="1.8"/>
                    <measurement group_id="O2" value="-0.81" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - Positive Score - Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.7" spread="3.6"/>
                    <measurement group_id="O2" value="21.8" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - Positive Score - Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3" spread="4.6"/>
                    <measurement group_id="O2" value="22.3" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - Positive Score - Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="3.8"/>
                    <measurement group_id="O2" value="0.5" spread="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.35</p_value>
            <p_value_desc>Exploratory efficacy outcome, hence no adjustment for multiple comparison.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.62</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.37</p_value>
            <p_value_desc>Exploratory efficacy outcome, hence no adjustment for multiple comparisons</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.62</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PANSS - Negative Subscale - Phases 1 and 2</title>
        <description>The Positive and Negative Syndrome Scale (PANSS) will be used to measure symptom severity in this trial. PANSS is a 30-item questionnaire used to evaluate schizophrenia symptoms, based on the clinical interview as well as reports of family members or primary care hospital workers. PANSS consists of Positive scale (7 items), Negative scale (7 items), and General Psychopathological scale (16 items) sections. Each item (symptom) will be scored on a 7-point scale with higher scores representing increasing levels of psychopathology: 1) Absent, 2) Minimal, 3) Mild, 4) Moderate, 5) Moderate severe, 6) Severe, and 7) Extreme. Negative scale: 7 Items, (minimum score = 7, maximum score = 49)</description>
        <time_frame>Phase 1 timeframe is Day 0 and Day 14; Phase 2 timeframe is Day 14 and Day 28</time_frame>
        <population>Ph 1 analysis includes the 34 subjects with Baseline PANSS data in the Placebo-Placebo (N=18) and Placebo-Drug (N=16) groups and 18 Drug-Drug group subjects. Per SPCD, the Ph 2 data excludes the 18 Drug-Drug group subjects and includes the 14 subjects in the Placebo-Drug group and 18 subjects in the Placebo-Placebo group with PANSS Baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Drug</title>
            <description>Phase 1 - intravenous sodium nitroprusside Phase 2 - intravenous sodium nitroprusside
sodium nitroprusside: intravenous</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Placebo</title>
            <description>Phase 1 - intravenous dextrose Phase 2 - intravenous dextrose
Placebo:</description>
          </group>
        </group_list>
        <measure>
          <title>PANSS - Negative Subscale - Phases 1 and 2</title>
          <description>The Positive and Negative Syndrome Scale (PANSS) will be used to measure symptom severity in this trial. PANSS is a 30-item questionnaire used to evaluate schizophrenia symptoms, based on the clinical interview as well as reports of family members or primary care hospital workers. PANSS consists of Positive scale (7 items), Negative scale (7 items), and General Psychopathological scale (16 items) sections. Each item (symptom) will be scored on a 7-point scale with higher scores representing increasing levels of psychopathology: 1) Absent, 2) Minimal, 3) Mild, 4) Moderate, 5) Moderate severe, 6) Severe, and 7) Extreme. Negative scale: 7 Items, (minimum score = 7, maximum score = 49)</description>
          <population>Ph 1 analysis includes the 34 subjects with Baseline PANSS data in the Placebo-Placebo (N=18) and Placebo-Drug (N=16) groups and 18 Drug-Drug group subjects. Per SPCD, the Ph 2 data excludes the 18 Drug-Drug group subjects and includes the 14 subjects in the Placebo-Drug group and 18 subjects in the Placebo-Placebo group with PANSS Baseline data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phase 1 - Negative Score - Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8" spread="5.8"/>
                    <measurement group_id="O2" value="20.6" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 1 - Negative Score - Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" spread="4.6"/>
                    <measurement group_id="O2" value="19.7" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 1 - Negative Score - Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="4.1"/>
                    <measurement group_id="O2" value="-1.0" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - Negative Score - Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5" spread="5.8"/>
                    <measurement group_id="O2" value="20.7" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - Negative Score - Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0" spread="6.2"/>
                    <measurement group_id="O2" value="19.8" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - Negative Score - Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.9"/>
                    <measurement group_id="O2" value="-0.9" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.85</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.12</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.88</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.10</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PANSS - General Psychopathology Subscale - Phases 1 and 2</title>
        <description>The Positive and Negative Syndrome Scale (PANSS) will be used to measure symptom severity in this trial. PANSS is a 30-item questionnaire used to evaluate schizophrenia symptoms, based on the clinical interview as well as reports of family members or primary care hospital workers. PANSS consists of Positive scale (7 items), Negative scale (7 items), and General Psychopathological scale (16 items) sections. Each item (symptom) will be scored on a 7-point scale with higher scores representing increasing levels of psychopathology: 1) Absent, 2) Minimal, 3) Mild, 4) Moderate, 5) Moderate severe, 6) Severe, and 7) Extreme. General Psychopathology Subscale: 16 Items, (minimum score = 16, maximum score = 112)</description>
        <time_frame>Phase 1 timeframe is Baseline and Day 14; Phase 2 timeframe is Day 14 and Day 28</time_frame>
        <population>Ph 1 analysis includes the 34 subjects with Baseline PANSS data in the Placebo-Placebo (N=18) and Placebo-Drug (N=16) groups and 18 Drug-Drug group subjects. Per SPCD, the Ph 2 data excludes the 18 Drug-Drug group subjects and includes the 14 subjects in the Placebo-Drug group and 18 subjects in the Placebo-Placebo group with PANSS Baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Drug</title>
            <description>Phase 1 - intravenous sodium nitroprusside Phase 2 - intravenous sodium nitroprusside
sodium nitroprusside: intravenous</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Placebo</title>
            <description>Phase 1 - intravenous dextrose Phase 2 - intravenous dextrose
Placebo:</description>
          </group>
        </group_list>
        <measure>
          <title>PANSS - General Psychopathology Subscale - Phases 1 and 2</title>
          <description>The Positive and Negative Syndrome Scale (PANSS) will be used to measure symptom severity in this trial. PANSS is a 30-item questionnaire used to evaluate schizophrenia symptoms, based on the clinical interview as well as reports of family members or primary care hospital workers. PANSS consists of Positive scale (7 items), Negative scale (7 items), and General Psychopathological scale (16 items) sections. Each item (symptom) will be scored on a 7-point scale with higher scores representing increasing levels of psychopathology: 1) Absent, 2) Minimal, 3) Mild, 4) Moderate, 5) Moderate severe, 6) Severe, and 7) Extreme. General Psychopathology Subscale: 16 Items, (minimum score = 16, maximum score = 112)</description>
          <population>Ph 1 analysis includes the 34 subjects with Baseline PANSS data in the Placebo-Placebo (N=18) and Placebo-Drug (N=16) groups and 18 Drug-Drug group subjects. Per SPCD, the Ph 2 data excludes the 18 Drug-Drug group subjects and includes the 14 subjects in the Placebo-Drug group and 18 subjects in the Placebo-Placebo group with PANSS Baseline data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phase 1 - General Score - Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.6" spread="6.0"/>
                    <measurement group_id="O2" value="36.4" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 1 - General Score - Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.3" spread="7.1"/>
                    <measurement group_id="O2" value="35.5" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 1 - General Score - Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="7.0"/>
                    <measurement group_id="O2" value="-0.6" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - General Score - Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.7" spread="6.4"/>
                    <measurement group_id="O2" value="36.2" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - General Score - Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.4" spread="5.6"/>
                    <measurement group_id="O2" value="32.4" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - General Score - Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="5.2"/>
                    <measurement group_id="O2" value="-3.7" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.86</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.19</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.83</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.23</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Percent Change From Baseline in the PANSS Total Score After 2 Weeks of Treatment Using SPCD</title>
        <description>The Positive and Negative Syndrome Scale (PANSS) will be used to measure symptom severity in this trial. PANSS is a 30-item questionnaire used to evaluate schizophrenia symptoms, based on the clinical interview as well as reports of family members or primary care hospital workers. PANSS consists of Positive scale (7 items), Negative scale (7 items), and General Psychopathological scale (16 items) sections. Each item (symptom) will be scored on a 7-point scale with higher scores representing increasing levels of psychopathology: 1) Absent, 2) Minimal, 3) Mild, 4) Moderate, 5) Moderate severe, 6) Severe, and 7) Extreme. Total score minimum = 30, maximum = 210.</description>
        <time_frame>For Phase 1, timeframe is Baseline and Day 14; Phase 2 timeframe is Day 14 and Day 28</time_frame>
        <population>Ph 1 analysis includes 34 subjects with Baseline PANSS data in the Placebo-Placebo (N=18) and Placebo-Drug (N=16) groups and 18 Drug-Drug group subjects. Per SPCD, the Ph 2 data excludes 18 subjects in the Drug-Drug group and includes the 14 subjects in the Placebo-Drug group and 18 subjects in the Placebo-Placebo group with PANSS Baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Drug</title>
            <description>Phase 1 - intravenous sodium nitroprusside Phase 2 - intravenous sodium nitroprusside
sodium nitroprusside: intravenous</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Phase 1 - intravenous dextrose Phase 2 - intravenous dextrose
Placebo:</description>
          </group>
        </group_list>
        <measure>
          <title>Average Percent Change From Baseline in the PANSS Total Score After 2 Weeks of Treatment Using SPCD</title>
          <description>The Positive and Negative Syndrome Scale (PANSS) will be used to measure symptom severity in this trial. PANSS is a 30-item questionnaire used to evaluate schizophrenia symptoms, based on the clinical interview as well as reports of family members or primary care hospital workers. PANSS consists of Positive scale (7 items), Negative scale (7 items), and General Psychopathological scale (16 items) sections. Each item (symptom) will be scored on a 7-point scale with higher scores representing increasing levels of psychopathology: 1) Absent, 2) Minimal, 3) Mild, 4) Moderate, 5) Moderate severe, 6) Severe, and 7) Extreme. Total score minimum = 30, maximum = 210.</description>
          <population>Ph 1 analysis includes 34 subjects with Baseline PANSS data in the Placebo-Placebo (N=18) and Placebo-Drug (N=16) groups and 18 Drug-Drug group subjects. Per SPCD, the Ph 2 data excludes 18 subjects in the Drug-Drug group and includes the 14 subjects in the Placebo-Drug group and 18 subjects in the Placebo-Placebo group with PANSS Baseline data.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phase 1 Average Percent Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.7" spread="12.8"/>
                    <measurement group_id="O2" value="-3.2" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 Average Percentage Change from Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="10.5"/>
                    <measurement group_id="O2" value="-3.3" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With 20% or More Reduction From Baseline in PANSS Total Score After 2 Weeks of Treatment Using SPCD</title>
        <description>The Positive and Negative Syndrome Scale (PANSS) will be used to measure symptom severity in this trial. PANSS is a 30-item questionnaire used to evaluate schizophrenia symptoms, based on the clinical interview as well as reports of family members or primary care hospital workers. PANSS consists of Positive scale (7 items), Negative scale (7 items), and General Psychopathological scale (16 items) sections. Each item (symptom) will be scored on a 7-point scale with higher scores representing increasing levels of psychopathology: 1) Absent, 2) Minimal, 3) Mild, 4) Moderate, 5) Moderate severe, 6) Severe, and 7) Extreme. Total score minimum = 30, maximum = 210.</description>
        <time_frame>For Phase 1, timeframe is Baseline and Day 14; Phase 2 timeframe is Day 14 and Day 28</time_frame>
        <population>Phase 1 analysis combines the 34 subjects assigned to Placebo-Placebo (N=18) and Placebo-Drug (N=16) groups and the 18 subjects assigned to the Drug-Drug group with complete data at all visits. Per SPCD, the Phase 2 data includes the 14 subjects in the Placebo-Drug group and 18 subjects in the Placebo-Placebo group with complete data at all visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Drug</title>
            <description>Phase 1 - intravenous sodium nitroprusside Phase 2 - intravenous sodium nitroprusside
sodium nitroprusside: intravenous</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Phase 1 - intravenous dextrose Phase 2 - intravenous dextrose
Placebo:</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With 20% or More Reduction From Baseline in PANSS Total Score After 2 Weeks of Treatment Using SPCD</title>
          <description>The Positive and Negative Syndrome Scale (PANSS) will be used to measure symptom severity in this trial. PANSS is a 30-item questionnaire used to evaluate schizophrenia symptoms, based on the clinical interview as well as reports of family members or primary care hospital workers. PANSS consists of Positive scale (7 items), Negative scale (7 items), and General Psychopathological scale (16 items) sections. Each item (symptom) will be scored on a 7-point scale with higher scores representing increasing levels of psychopathology: 1) Absent, 2) Minimal, 3) Mild, 4) Moderate, 5) Moderate severe, 6) Severe, and 7) Extreme. Total score minimum = 30, maximum = 210.</description>
          <population>Phase 1 analysis combines the 34 subjects assigned to Placebo-Placebo (N=18) and Placebo-Drug (N=16) groups and the 18 subjects assigned to the Drug-Drug group with complete data at all visits. Per SPCD, the Phase 2 data includes the 14 subjects in the Placebo-Drug group and 18 subjects in the Placebo-Placebo group with complete data at all visits.</population>
          <units>percent of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phase 1 % of subjects with &gt;=20% reduction</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.67"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 % of subjects with &gt;=20% reduction</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Percent Change From Baseline in the PANSS Positive Subscale Score After 2 Weeks of Treatment Using SPCD</title>
        <description>The Positive and Negative Syndrome Scale (PANSS) will be used to measure symptom severity in this trial. PANSS is a 30-item questionnaire used to evaluate schizophrenia symptoms, based on the clinical interview as well as reports of family members or primary care hospital workers. PANSS consists of Positive scale (7 items), Negative scale (7 items), and General Psychopathological scale (16 items) sections. Each item (symptom) will be scored on a 7-point scale with higher scores representing increasing levels of psychopathology: 1) Absent, 2) Minimal, 3) Mild, 4) Moderate, 5) Moderate severe, 6) Severe, and 7) Extreme. Positive subscore scale: 7 items (minimum score = 7; maximum score = 49)</description>
        <time_frame>For Phase 1, timeframe is Baseline and Day 14; Phase 2 timeframe is Day 14 and Day 28</time_frame>
        <population>Ph 1 analysis includes 34 subjects with Baseline PANSS data in the Placebo-Placebo (N=18) and Placebo-Drug (N=16) groups and 18 Drug-Drug group subjects. Per SPCD, the Ph 2 data excludes 18 subjects in the Drug-Drug group and includes the 14 subjects in the Placebo-Drug group and 18 subjects in the Placebo-Placebo group with PANSS Baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Drug</title>
            <description>Phase 1 - intravenous sodium nitroprusside Phase 2 - intravenous sodium nitroprusside
sodium nitroprusside: intravenous</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Phase 1 - intravenous dextrose Phase 2 - intravenous dextrose
Placebo:</description>
          </group>
        </group_list>
        <measure>
          <title>Average Percent Change From Baseline in the PANSS Positive Subscale Score After 2 Weeks of Treatment Using SPCD</title>
          <description>The Positive and Negative Syndrome Scale (PANSS) will be used to measure symptom severity in this trial. PANSS is a 30-item questionnaire used to evaluate schizophrenia symptoms, based on the clinical interview as well as reports of family members or primary care hospital workers. PANSS consists of Positive scale (7 items), Negative scale (7 items), and General Psychopathological scale (16 items) sections. Each item (symptom) will be scored on a 7-point scale with higher scores representing increasing levels of psychopathology: 1) Absent, 2) Minimal, 3) Mild, 4) Moderate, 5) Moderate severe, 6) Severe, and 7) Extreme. Positive subscore scale: 7 items (minimum score = 7; maximum score = 49)</description>
          <population>Ph 1 analysis includes 34 subjects with Baseline PANSS data in the Placebo-Placebo (N=18) and Placebo-Drug (N=16) groups and 18 Drug-Drug group subjects. Per SPCD, the Ph 2 data excludes 18 subjects in the Drug-Drug group and includes the 14 subjects in the Placebo-Drug group and 18 subjects in the Placebo-Placebo group with PANSS Baseline data.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phase 1 Average Percent Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.9" spread="8.1"/>
                    <measurement group_id="O2" value="-3.2" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 Average Percentage Change from Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="15.4"/>
                    <measurement group_id="O2" value="-2.9" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Percent Change From Baseline in the PANSS Negative Subscale Score After 2 Weeks of Treatment Using SPCD</title>
        <description>The Positive and Negative Syndrome Scale (PANSS) will be used to measure symptom severity in this trial. PANSS is a 30-item questionnaire used to evaluate schizophrenia symptoms, based on the clinical interview as well as reports of family members or primary care hospital workers. PANSS consists of Positive scale (7 items), Negative scale (7 items), and General Psychopathological scale (16 items) sections. Each item (symptom) will be scored on a 7-point scale with higher scores representing increasing levels of psychopathology: 1) Absent, 2) Minimal, 3) Mild, 4) Moderate, 5) Moderate severe, 6) Severe, and 7) Extreme. Negative subscore scale: 7 items (minimum score = 7; maximum score = 49)</description>
        <time_frame>For Phase 1, timeframe is Baseline and Day 14; Phase 2 timeframe is Day 14 and Day 28</time_frame>
        <population>Phase 1 analysis combines the 34 subjects assigned to Placebo-Placebo (N=18) and Placebo-Drug (N=16) groups and the 18 subjects assigned to the Drug-Drug group with complete data at all visits. Per SPCD, the Phase 2 data includes the 14 subjects in the Placebo-Drug group and 18 subjects in the Placebo-Placebo group with complete data at all visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Drug</title>
            <description>Phase 1 - intravenous sodium nitroprusside Phase 2 - intravenous sodium nitroprusside
sodium nitroprusside: intravenous</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Phase 1 - intravenous dextrose Phase 2 - intravenous dextrose
Placebo:</description>
          </group>
        </group_list>
        <measure>
          <title>Average Percent Change From Baseline in the PANSS Negative Subscale Score After 2 Weeks of Treatment Using SPCD</title>
          <description>The Positive and Negative Syndrome Scale (PANSS) will be used to measure symptom severity in this trial. PANSS is a 30-item questionnaire used to evaluate schizophrenia symptoms, based on the clinical interview as well as reports of family members or primary care hospital workers. PANSS consists of Positive scale (7 items), Negative scale (7 items), and General Psychopathological scale (16 items) sections. Each item (symptom) will be scored on a 7-point scale with higher scores representing increasing levels of psychopathology: 1) Absent, 2) Minimal, 3) Mild, 4) Moderate, 5) Moderate severe, 6) Severe, and 7) Extreme. Negative subscore scale: 7 items (minimum score = 7; maximum score = 49)</description>
          <population>Phase 1 analysis combines the 34 subjects assigned to Placebo-Placebo (N=18) and Placebo-Drug (N=16) groups and the 18 subjects assigned to the Drug-Drug group with complete data at all visits. Per SPCD, the Phase 2 data includes the 14 subjects in the Placebo-Drug group and 18 subjects in the Placebo-Placebo group with complete data at all visits.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phase 1 Average Percent Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.1" spread="17.6"/>
                    <measurement group_id="O2" value="-4.6" spread="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 Average Percentage Change from Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.9" spread="12.3"/>
                    <measurement group_id="O2" value="-2.1" spread="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Percent Change From Baseline in the PANSS General Psychopathology Subscale Score After 2 Weeks of Treatment Using SPCD</title>
        <description>The Positive and Negative Syndrome Scale (PANSS) will be used to measure symptom severity in this trial. PANSS is a 30-item questionnaire used to evaluate schizophrenia symptoms, based on the clinical interview as well as reports of family members or primary care hospital workers. PANSS consists of Positive scale (7 items), Negative scale (7 items), and General Psychopathological scale (16 items) sections. Each item (symptom) will be scored on a 7-point scale with higher scores representing increasing levels of psychopathology: 1) Absent, 2) Minimal, 3) Mild, 4) Moderate, 5) Moderate severe, 6) Severe, and 7) Extreme. General Psychopathology subscore scale: 16 items (minimum score = 16; maximum score = 112)</description>
        <time_frame>For Phase 1, timeframe is Baseline and Day 14; Phase 2 timeframe is Day 14 and Day 28</time_frame>
        <population>Ph 1 analysis includes 34 subjects with Baseline PANSS data in the Placebo-Placebo (N=18) and Placebo-Drug (N=16) groups and 18 Drug-Drug group subjects. Per SPCD, the Ph 2 data excludes 18 subjects in the Drug-Drug group and includes the 14 subjects in the Placebo-Drug group and 18 subjects in the Placebo-Placebo group with PANSS Baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Drug</title>
            <description>Phase 1 - intravenous sodium nitroprusside Phase 2 - intravenous sodium nitroprusside
sodium nitroprusside: intravenous</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Phase 1 - intravenous dextrose Phase 2 - intravenous dextrose
Placebo:</description>
          </group>
        </group_list>
        <measure>
          <title>Average Percent Change From Baseline in the PANSS General Psychopathology Subscale Score After 2 Weeks of Treatment Using SPCD</title>
          <description>The Positive and Negative Syndrome Scale (PANSS) will be used to measure symptom severity in this trial. PANSS is a 30-item questionnaire used to evaluate schizophrenia symptoms, based on the clinical interview as well as reports of family members or primary care hospital workers. PANSS consists of Positive scale (7 items), Negative scale (7 items), and General Psychopathological scale (16 items) sections. Each item (symptom) will be scored on a 7-point scale with higher scores representing increasing levels of psychopathology: 1) Absent, 2) Minimal, 3) Mild, 4) Moderate, 5) Moderate severe, 6) Severe, and 7) Extreme. General Psychopathology subscore scale: 16 items (minimum score = 16; maximum score = 112)</description>
          <population>Ph 1 analysis includes 34 subjects with Baseline PANSS data in the Placebo-Placebo (N=18) and Placebo-Drug (N=16) groups and 18 Drug-Drug group subjects. Per SPCD, the Ph 2 data excludes 18 subjects in the Drug-Drug group and includes the 14 subjects in the Placebo-Drug group and 18 subjects in the Placebo-Placebo group with PANSS Baseline data.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phase 1 Average Percent Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.8" spread="18.3"/>
                    <measurement group_id="O2" value="-1.8" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 Average Percentage Change from Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" spread="13.3"/>
                    <measurement group_id="O2" value="-3.7" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) - Phases 1 and 2</title>
        <description>MATRICS: The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB). The MATRICS Consensus Cognitive Battery is the standard tool for assessing cognitive change in trials of cognitive-enhancing agents in schizophrenia. The MCCB domains include: Speed of Processing; Attention/Vigilance; Working Memory; Verbal Learning; Visual Learning; Reasoning &amp; Problem-Solving; and Social Cognition and the battery takes about 80 minutes to complete. The MCCB composite score represents a global measure of cognition. MCCB composite T scores are between 40 and 60 (normal range) and &lt; 40 (below normal range).</description>
        <time_frame>Phase 1 timeframe is Baseline and Day 14; Phase 2 timeframe is Day 14 and Day 28</time_frame>
        <population>Ph1 analysis includes 34 subjects with Baseline MATRICS data in the Placebo-Placebo (N=18) and Placebo-Drug (N=16) groups and 18 subjects the Drug-Drug group. Per SPCD, Ph 2 excludes the 18 subjects in the Drug-Drug group and includes the 14 subjects in the Placebo-Drug group and 18 subjects in the Placebo-Placebo group with Baseline MATRICS data.</population>
        <group_list>
          <group group_id="O1">
            <title>Drug</title>
            <description>Phase 1 - intravenous sodium nitroprusside Phase 2 - intravenous sodium nitroprusside
sodium nitroprusside: intravenous</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Placebo</title>
            <description>Phase 1 - intravenous dextrose Phase 2 - intravenous dextrose
Placebo:</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) - Phases 1 and 2</title>
          <description>MATRICS: The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB). The MATRICS Consensus Cognitive Battery is the standard tool for assessing cognitive change in trials of cognitive-enhancing agents in schizophrenia. The MCCB domains include: Speed of Processing; Attention/Vigilance; Working Memory; Verbal Learning; Visual Learning; Reasoning &amp; Problem-Solving; and Social Cognition and the battery takes about 80 minutes to complete. The MCCB composite score represents a global measure of cognition. MCCB composite T scores are between 40 and 60 (normal range) and &lt; 40 (below normal range).</description>
          <population>Ph1 analysis includes 34 subjects with Baseline MATRICS data in the Placebo-Placebo (N=18) and Placebo-Drug (N=16) groups and 18 subjects the Drug-Drug group. Per SPCD, Ph 2 excludes the 18 subjects in the Drug-Drug group and includes the 14 subjects in the Placebo-Drug group and 18 subjects in the Placebo-Placebo group with Baseline MATRICS data.</population>
          <units>T-scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phase 1 - Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2" spread="14.3"/>
                    <measurement group_id="O2" value="26.5" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 1 - Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.3" spread="12.9"/>
                    <measurement group_id="O2" value="28.6" spread="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 1 - Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="3.9"/>
                    <measurement group_id="O2" value="1.4" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.8" spread="12.8"/>
                    <measurement group_id="O2" value="28.4" spread="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.3" spread="13.6"/>
                    <measurement group_id="O2" value="31.0" spread="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="4.2"/>
                    <measurement group_id="O2" value="2.6" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.33</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.12</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.34</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.10</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Average AIMS Total Scores (Items 1-7) by Group and Timepoint</title>
        <description>Abnormal Involuntary Movement Scale (AIMS):
The AIMS Total Dyskinesia Score was calculated by averaging the first 7 items of the AIMS. The 7 items included in the AIMS Dyskinesia Score are rated on a scale from 0 (no dyskinesia) to 4 (severe dyskinesia). Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). The AIMS dyskinesia total score ranges from 0 to 4; a higher score reflects increased severity.</description>
        <time_frame>Baseline 1 (Day -1), 7 Hours Post-Infusion 1, Baseline 2 (Day 13), 7 Hours Post-Infusion 2, Final Follow-Up, including early termination visits</time_frame>
        <population>Includes all subjects with AIMS data at Phases 1 and 2</population>
        <group_list>
          <group group_id="O1">
            <title>Drug - Drug</title>
            <description>Phase 1 - intravenous sodium nitroprusside Phase 2 - intravenous sodium nitroprusside
sodium nitroprusside: intravenous</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Drug</title>
            <description>Phase 1 - intravenous dextrose Phase 2 - intravenous sodium nitroprusside
sodium nitroprusside: intravenous</description>
          </group>
          <group group_id="O3">
            <title>Placebo - Placebo</title>
            <description>Phase 1 - intravenous dextrose Phase 2 - intravenous dextrose
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Average AIMS Total Scores (Items 1-7) by Group and Timepoint</title>
          <description>Abnormal Involuntary Movement Scale (AIMS):
The AIMS Total Dyskinesia Score was calculated by averaging the first 7 items of the AIMS. The 7 items included in the AIMS Dyskinesia Score are rated on a scale from 0 (no dyskinesia) to 4 (severe dyskinesia). Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). The AIMS dyskinesia total score ranges from 0 to 4; a higher score reflects increased severity.</description>
          <population>Includes all subjects with AIMS data at Phases 1 and 2</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72" spread="1.41"/>
                    <measurement group_id="O2" value="0.56" spread="0.96"/>
                    <measurement group_id="O3" value="0.56" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 Hours Post-Infusion 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" spread="1.10"/>
                    <measurement group_id="O2" value="0.31" spread="0.48"/>
                    <measurement group_id="O3" value="0.31" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="0.92"/>
                    <measurement group_id="O2" value="1.00" spread="1.47"/>
                    <measurement group_id="O3" value="1.00" spread="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 Hours Post-Infusion 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" spread="0.87"/>
                    <measurement group_id="O2" value="0.54" spread="0.88"/>
                    <measurement group_id="O3" value="0.54" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="2.09"/>
                    <measurement group_id="O2" value="0.93" spread="1.67"/>
                    <measurement group_id="O3" value="0.93" spread="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent of Participants Rated as ≥ &quot;Mild&quot; or as &quot;Yes&quot; on AIMS Items 8-12</title>
        <description>Abnormal Involuntary Movement Scale (AIMS):
The AIMS is a 12-item anchored score that is clinician administered and scored. Items are scored on a 0 (none) to 4 (severe) basis; items 8-10 deal with global severity; items 11-12 are yes-no questions concerning problems with teeth and/or dentures.</description>
        <time_frame>Baseline (Day -1), Follow-Up = reported at any assessment thereafter, including 7 hours after Infusions #1 and #2, Baseline 2 (Day 13) and final follow-up, including early termination visits.</time_frame>
        <population>For each item, percentages of participants rated as exhibiting behaviors at the “mild” level or higher, or for items 11 and 12, as being present versus not (yes/no rated) are provided per treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>Drug - Drug</title>
            <description>Phase 1 - intravenous sodium nitroprusside Phase 2 - intravenous sodium nitroprusside
sodium nitroprusside: intravenous</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Drug</title>
            <description>Phase 1 - intravenous dextrose Phase 2 - intravenous sodium nitroprusside
sodium nitroprusside: intravenous</description>
          </group>
          <group group_id="O3">
            <title>Placebo - Placebo</title>
            <description>Phase 1 - intravenous dextrose Phase 2 - intravenous dextrose
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Rated as ≥ &quot;Mild&quot; or as &quot;Yes&quot; on AIMS Items 8-12</title>
          <description>Abnormal Involuntary Movement Scale (AIMS):
The AIMS is a 12-item anchored score that is clinician administered and scored. Items are scored on a 0 (none) to 4 (severe) basis; items 8-10 deal with global severity; items 11-12 are yes-no questions concerning problems with teeth and/or dentures.</description>
          <population>For each item, percentages of participants rated as exhibiting behaviors at the “mild” level or higher, or for items 11 and 12, as being present versus not (yes/no rated) are provided per treatment group.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline - Overall Severity Index (Item 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                    <measurement group_id="O2" value="6.3"/>
                    <measurement group_id="O3" value="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-Up - Overall Severity Index (Item 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="18.8"/>
                    <measurement group_id="O3" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - Incapacitation (Item 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-Up - Incapacitation (Item 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="6.3"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - Awareness (Item 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1"/>
                    <measurement group_id="O2" value="6.3"/>
                    <measurement group_id="O3" value="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-Up - Awareness (Item 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                    <measurement group_id="O2" value="18.8"/>
                    <measurement group_id="O3" value="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - Dental Problem (Item 11; % yes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2"/>
                    <measurement group_id="O2" value="31.3"/>
                    <measurement group_id="O3" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-Up - Dental Problem (Item 11; % yes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8"/>
                    <measurement group_id="O2" value="37.5"/>
                    <measurement group_id="O3" value="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - Dentures (Item 12; % yes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                    <measurement group_id="O2" value="18.8"/>
                    <measurement group_id="O3" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-Up - Dentures (Item 12; % yes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1"/>
                    <measurement group_id="O2" value="31.3"/>
                    <measurement group_id="O3" value="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in The University of California San Diego (UCSD) Performance-based Skills Assessment Brief (UPSA-B) - Phases 1 and 2</title>
        <description>The University of California San Diego (UCSD) Performance-based Skills Assessment Brief (UPSA-B) consists of two of the five original UPSA domains, finances and communication. Each subscale contributes 50 points; total scores range from 0 to 100 points with higher scores reflecting better performance.</description>
        <time_frame>Phase 1 timeframe is Baseline and Day 14; Phase 2 timeframe is Day 14 and Day 28</time_frame>
        <population>Ph1 analysis includes 34 subjects with Baseline UPSA-B data in the Placebo-Placebo (N=18) and Placebo-Drug (N=16) groups and 18 subjects the Drug-Drug group. Per SPCD, Ph 2 excludes the 18 subjects in the Drug-Drug group and includes the 14 subjects in the Placebo-Drug group and 18 subjects in the Placebo-Placebo group with Baseline UPSA-B data.</population>
        <group_list>
          <group group_id="O1">
            <title>Drug</title>
            <description>Phase 1 - intravenous sodium nitroprusside Phase 2 - intravenous sodium nitroprusside
sodium nitroprusside: intravenous</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Placebo</title>
            <description>Phase 1 - intravenous dextrose Phase 2 - intravenous dextrose
Placebo:</description>
          </group>
        </group_list>
        <measure>
          <title>Change in The University of California San Diego (UCSD) Performance-based Skills Assessment Brief (UPSA-B) - Phases 1 and 2</title>
          <description>The University of California San Diego (UCSD) Performance-based Skills Assessment Brief (UPSA-B) consists of two of the five original UPSA domains, finances and communication. Each subscale contributes 50 points; total scores range from 0 to 100 points with higher scores reflecting better performance.</description>
          <population>Ph1 analysis includes 34 subjects with Baseline UPSA-B data in the Placebo-Placebo (N=18) and Placebo-Drug (N=16) groups and 18 subjects the Drug-Drug group. Per SPCD, Ph 2 excludes the 18 subjects in the Drug-Drug group and includes the 14 subjects in the Placebo-Drug group and 18 subjects in the Placebo-Placebo group with Baseline UPSA-B data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phase 1 - Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.0" spread="17.2"/>
                    <measurement group_id="O2" value="71.8" spread="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 1 - Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.7" spread="17.4"/>
                    <measurement group_id="O2" value="77.9" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 1 - Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="7.6"/>
                    <measurement group_id="O2" value="6.2" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.2" spread="13.1"/>
                    <measurement group_id="O2" value="76.0" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.4" spread="11.2"/>
                    <measurement group_id="O2" value="74.5" spread="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="7.7"/>
                    <measurement group_id="O2" value="-1.5" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.34</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.11</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.36</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.05</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants Reporting Suicidal Ideation/Behavior on the Columbia Suicide Severity Rating Scale (C-SSRS)</title>
        <description>The Columbia Suicide Severity Rating Scale (C-SSRS): The C-SSRS is a low-burden measure of the spectrum of suicidal ideation and behavior that was developed in the National Institute of Mental Health Treatment of Adolescent Suicide Attempters Study to assess severity and track suicidal events through any treatment. It is a clinical interview providing a summary of both ideation and behavior that can be administered during any evaluation or risk assessment to identify the level and type of suicidality present. The C-SSRS can also be used during treatment to monitor for clinical worsening or improvement. It contains 5 rating scale questions (yes/no) for suicidal ideation increasing severity and 5 rating scale questions (yes/no) for suicidal behavior of increasing severity. The time frame is for both lifetime and the past six months for the Baseline/Screening scale and since the last visit for the Since Last Visit scale.</description>
        <time_frame>Screening Visit, Days 3 (Baseline 1), Days 7, 13 (Baseline 2), 21 and 28</time_frame>
        <population>All subjects with C-SSRS data reporting suicidal ideation/behavior</population>
        <group_list>
          <group group_id="O1">
            <title>Drug - Drug</title>
            <description>Phase 1 - intravenous sodium nitroprusside Phase 2 - intravenous sodium nitroprusside
sodium nitroprusside: intravenous</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Drug</title>
            <description>Phase 1 - intravenous dextrose Phase 2 - intravenous sodium nitroprusside
sodium nitroprusside: intravenous</description>
          </group>
          <group group_id="O3">
            <title>Placebo - Placebo</title>
            <description>Phase 1 - intravenous dextrose Phase 2 - intravenous dextrose
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Suicidal Ideation/Behavior on the Columbia Suicide Severity Rating Scale (C-SSRS)</title>
          <description>The Columbia Suicide Severity Rating Scale (C-SSRS): The C-SSRS is a low-burden measure of the spectrum of suicidal ideation and behavior that was developed in the National Institute of Mental Health Treatment of Adolescent Suicide Attempters Study to assess severity and track suicidal events through any treatment. It is a clinical interview providing a summary of both ideation and behavior that can be administered during any evaluation or risk assessment to identify the level and type of suicidality present. The C-SSRS can also be used during treatment to monitor for clinical worsening or improvement. It contains 5 rating scale questions (yes/no) for suicidal ideation increasing severity and 5 rating scale questions (yes/no) for suicidal behavior of increasing severity. The time frame is for both lifetime and the past six months for the Baseline/Screening scale and since the last visit for the Since Last Visit scale.</description>
          <population>All subjects with C-SSRS data reporting suicidal ideation/behavior</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Suicidal ideation (SI) (% any of the following)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wish to be dead</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-specific active suicidal thoughts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Active SI w/any method (no plan) W/O intent to act</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Active SI w/some intent to act, W/O specific plan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Active SI with specific plan &amp; intent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal behavior (% any of the following)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prepatory acts or behavior</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aborted attempt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interrupted attempt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-fatal suicide attempt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Self-injurious behavior W/O suicidal intent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Systolic Blood Pressure Per Infusion Phase by Group</title>
        <description>Infusion 1 (Day 0) - Systolic Blood Pressure at all time points by group
&quot;Phase&quot; in this analysis refers to the infusion stage as defined in the protocol.</description>
        <time_frame>Day 0 - Phase 1 - Baseline = min000s1 and @5 min; Phase 2 - Baseline = min000 then every 10 minutes for 4 hours; Post Infusion - Baseline = min000, then every 10 minutes for 2 hours</time_frame>
        <population>Includes all subjects during Phase 1 (i.e., infusion 1)</population>
        <group_list>
          <group group_id="O1">
            <title>Drug-Drug</title>
            <description>Phase 1 - intravenous sodium nitroprusside Phase 2 - intravenous sodium nitroprusside
sodium nitroprusside: intravenous</description>
          </group>
          <group group_id="O2">
            <title>Placebo-Drug</title>
            <description>Phase 1 - intravenous dextrose Phase 2 - intravenous sodium nitroprusside</description>
          </group>
          <group group_id="O3">
            <title>Placebo - Placebo</title>
            <description>Phase 1 - intravenous dextrose Phase 2 - intravenous dextrose
Placebo:</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure Per Infusion Phase by Group</title>
          <description>Infusion 1 (Day 0) - Systolic Blood Pressure at all time points by group
&quot;Phase&quot; in this analysis refers to the infusion stage as defined in the protocol.</description>
          <population>Includes all subjects during Phase 1 (i.e., infusion 1)</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phase 1 - min000s1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.79" spread="14.46"/>
                    <measurement group_id="O2" value="121.50" spread="10.65"/>
                    <measurement group_id="O3" value="123.78" spread="11.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 1 - min005s1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.95" spread="12.78"/>
                    <measurement group_id="O2" value="126.13" spread="13.01"/>
                    <measurement group_id="O3" value="121.94" spread="14.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min000</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.89" spread="13.13"/>
                    <measurement group_id="O2" value="125.13" spread="11.04"/>
                    <measurement group_id="O3" value="121.00" spread="12.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min005</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.32" spread="11.51"/>
                    <measurement group_id="O2" value="124.38" spread="10.29"/>
                    <measurement group_id="O3" value="121.00" spread="14.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min010</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.72" spread="12.84"/>
                    <measurement group_id="O2" value="127.06" spread="8.93"/>
                    <measurement group_id="O3" value="122.33" spread="11.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min015</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.28" spread="9.48"/>
                    <measurement group_id="O2" value="125.75" spread="10.51"/>
                    <measurement group_id="O3" value="121.94" spread="11.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min020</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.28" spread="10.21"/>
                    <measurement group_id="O2" value="124.63" spread="9.94"/>
                    <measurement group_id="O3" value="121.11" spread="10.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min025</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.83" spread="10.70"/>
                    <measurement group_id="O2" value="126.63" spread="11.89"/>
                    <measurement group_id="O3" value="121.11" spread="11.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min030</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.61" spread="10.01"/>
                    <measurement group_id="O2" value="125.13" spread="9.84"/>
                    <measurement group_id="O3" value="119.67" spread="13.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min040</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.82" spread="9.80"/>
                    <measurement group_id="O2" value="125.63" spread="11.86"/>
                    <measurement group_id="O3" value="122.56" spread="11.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min050</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.00" spread="8.89"/>
                    <measurement group_id="O2" value="125.73" spread="9.32"/>
                    <measurement group_id="O3" value="122.56" spread="11.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min060</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.53" spread="11.99"/>
                    <measurement group_id="O2" value="126.87" spread="9.69"/>
                    <measurement group_id="O3" value="120.17" spread="12.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min070</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.82" spread="12.83"/>
                    <measurement group_id="O2" value="126.27" spread="8.86"/>
                    <measurement group_id="O3" value="120.11" spread="10.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min080</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.00" spread="9.98"/>
                    <measurement group_id="O2" value="125.53" spread="9.62"/>
                    <measurement group_id="O3" value="120.83" spread="13.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min090</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.94" spread="9.83"/>
                    <measurement group_id="O2" value="125.00" spread="11.14"/>
                    <measurement group_id="O3" value="121.33" spread="12.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min100</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.00" spread="12.97"/>
                    <measurement group_id="O2" value="123.87" spread="11.75"/>
                    <measurement group_id="O3" value="122.11" spread="12.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min110</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.29" spread="7.83"/>
                    <measurement group_id="O2" value="128.33" spread="10.60"/>
                    <measurement group_id="O3" value="122.83" spread="12.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.76" spread="10.56"/>
                    <measurement group_id="O2" value="124.93" spread="12.57"/>
                    <measurement group_id="O3" value="119.06" spread="15.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min130</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.82" spread="9.19"/>
                    <measurement group_id="O2" value="125.20" spread="8.99"/>
                    <measurement group_id="O3" value="119.17" spread="10.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min140</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.47" spread="7.34"/>
                    <measurement group_id="O2" value="127.67" spread="9.76"/>
                    <measurement group_id="O3" value="119.72" spread="11.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min150</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.12" spread="9.62"/>
                    <measurement group_id="O2" value="126.93" spread="10.75"/>
                    <measurement group_id="O3" value="123.39" spread="12.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min160</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.88" spread="9.97"/>
                    <measurement group_id="O2" value="126.00" spread="9.56"/>
                    <measurement group_id="O3" value="121.72" spread="15.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min170</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.35" spread="11.89"/>
                    <measurement group_id="O2" value="124.33" spread="9.51"/>
                    <measurement group_id="O3" value="122.72" spread="15.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min180</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.06" spread="9.85"/>
                    <measurement group_id="O2" value="127.07" spread="12.63"/>
                    <measurement group_id="O3" value="123.22" spread="13.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min190</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.12" spread="11.60"/>
                    <measurement group_id="O2" value="125.13" spread="13.10"/>
                    <measurement group_id="O3" value="121.94" spread="12.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min200</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.41" spread="12.57"/>
                    <measurement group_id="O2" value="125.40" spread="13.00"/>
                    <measurement group_id="O3" value="122.67" spread="14.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min210</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.71" spread="8.08"/>
                    <measurement group_id="O2" value="131.87" spread="13.79"/>
                    <measurement group_id="O3" value="122.94" spread="11.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min220</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.82" spread="9.57"/>
                    <measurement group_id="O2" value="125.73" spread="13.24"/>
                    <measurement group_id="O3" value="125.89" spread="14.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min230</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.35" spread="9.57"/>
                    <measurement group_id="O2" value="126.00" spread="13.80"/>
                    <measurement group_id="O3" value="124.61" spread="13.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min240</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.53" spread="9.13"/>
                    <measurement group_id="O2" value="128.67" spread="14.01"/>
                    <measurement group_id="O3" value="124.44" spread="14.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min000</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.50" spread="11.53"/>
                    <measurement group_id="O2" value="128.38" spread="13.87"/>
                    <measurement group_id="O3" value="125.22" spread="13.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min005</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.44" spread="11.01"/>
                    <measurement group_id="O2" value="126.13" spread="13.84"/>
                    <measurement group_id="O3" value="123.12" spread="10.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min010</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.28" spread="11.74"/>
                    <measurement group_id="O2" value="127.33" spread="12.80"/>
                    <measurement group_id="O3" value="122.06" spread="11.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min015</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.22" spread="11.07"/>
                    <measurement group_id="O2" value="128.40" spread="16.79"/>
                    <measurement group_id="O3" value="124.67" spread="11.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min020</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.39" spread="9.12"/>
                    <measurement group_id="O2" value="128.80" spread="13.04"/>
                    <measurement group_id="O3" value="124.50" spread="12.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min025</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.33" spread="12.58"/>
                    <measurement group_id="O2" value="129.53" spread="14.94"/>
                    <measurement group_id="O3" value="126.72" spread="14.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min030</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.56" spread="11.93"/>
                    <measurement group_id="O2" value="129.81" spread="13.96"/>
                    <measurement group_id="O3" value="124.00" spread="14.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min040</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.67" spread="12.03"/>
                    <measurement group_id="O2" value="128.33" spread="14.99"/>
                    <measurement group_id="O3" value="123.33" spread="14.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min050</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.33" spread="13.91"/>
                    <measurement group_id="O2" value="128.47" spread="11.86"/>
                    <measurement group_id="O3" value="123.11" spread="13.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min060</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.22" spread="12.35"/>
                    <measurement group_id="O2" value="129.93" spread="12.21"/>
                    <measurement group_id="O3" value="124.61" spread="14.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min070</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.33" spread="13.78"/>
                    <measurement group_id="O2" value="130.27" spread="11.51"/>
                    <measurement group_id="O3" value="122.72" spread="15.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min080</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.83" spread="12.78"/>
                    <measurement group_id="O2" value="128.47" spread="11.86"/>
                    <measurement group_id="O3" value="122.94" spread="14.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min090</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.67" spread="12.56"/>
                    <measurement group_id="O2" value="129.20" spread="13.03"/>
                    <measurement group_id="O3" value="124.06" spread="10.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min100</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.44" spread="11.87"/>
                    <measurement group_id="O2" value="125.67" spread="11.63"/>
                    <measurement group_id="O3" value="121.72" spread="10.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min110</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.61" spread="13.42"/>
                    <measurement group_id="O2" value="129.27" spread="11.49"/>
                    <measurement group_id="O3" value="125.06" spread="14.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.22" spread="13.41"/>
                    <measurement group_id="O2" value="128.67" spread="10.99"/>
                    <measurement group_id="O3" value="124.44" spread="12.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Diastolic Blood Pressure Per Infusion Phase by Group</title>
        <description>Infusion 1 (Day 0) - Diastolic Blood Pressure at all time points by group
&quot;Phase&quot; in this analysis refers to the infusion stage as defined in the protocol.</description>
        <time_frame>Day 0 - Phase 1 - Baseline = min000s1 and @5 min; Phase 2 - Baseline = min000 then every 10 minutes for 4 hours; Post Infusion - Baseline = min000, then every 10 minutes for 2 hours</time_frame>
        <population>Includes all subjects during Phase 1 (i.e., infusion 1)</population>
        <group_list>
          <group group_id="O1">
            <title>Drug-Drug</title>
            <description>Phase 1 - intravenous sodium nitroprusside Phase 2 - intravenous sodium nitroprusside
sodium nitroprusside: intravenous</description>
          </group>
          <group group_id="O2">
            <title>Placebo-Drug</title>
            <description>Phase 1 - intravenous dextrose Phase 2 - intravenous sodium nitroprusside</description>
          </group>
          <group group_id="O3">
            <title>Placebo - Placebo</title>
            <description>Phase 1 - intravenous dextrose Phase 2 - intravenous dextrose
Placebo:</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure Per Infusion Phase by Group</title>
          <description>Infusion 1 (Day 0) - Diastolic Blood Pressure at all time points by group
&quot;Phase&quot; in this analysis refers to the infusion stage as defined in the protocol.</description>
          <population>Includes all subjects during Phase 1 (i.e., infusion 1)</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phase 1 - min000s1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.63" spread="19.03"/>
                    <measurement group_id="O2" value="75.13" spread="10.44"/>
                    <measurement group_id="O3" value="75.11" spread="10.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 1 - min005s1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.79" spread="10.12"/>
                    <measurement group_id="O2" value="75.38" spread="6.30"/>
                    <measurement group_id="O3" value="74.94" spread="9.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min000</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.58" spread="10.18"/>
                    <measurement group_id="O2" value="74.44" spread="7.28"/>
                    <measurement group_id="O3" value="74.72" spread="11.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min005</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.37" spread="12.88"/>
                    <measurement group_id="O2" value="74.31" spread="7.01"/>
                    <measurement group_id="O3" value="74.39" spread="8.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min010</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.72" spread="14.70"/>
                    <measurement group_id="O2" value="75.50" spread="8.09"/>
                    <measurement group_id="O3" value="73.72" spread="9.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min015</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.67" spread="9.94"/>
                    <measurement group_id="O2" value="74.75" spread="8.38"/>
                    <measurement group_id="O3" value="72.78" spread="8.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min020</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.06" spread="9.33"/>
                    <measurement group_id="O2" value="75.19" spread="8.29"/>
                    <measurement group_id="O3" value="74.33" spread="12.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min025</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.33" spread="8.61"/>
                    <measurement group_id="O2" value="74.31" spread="6.02"/>
                    <measurement group_id="O3" value="72.83" spread="11.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min030</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.78" spread="8.93"/>
                    <measurement group_id="O2" value="75.50" spread="8.09"/>
                    <measurement group_id="O3" value="72.06" spread="11.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min040</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.29" spread="7.46"/>
                    <measurement group_id="O2" value="75.06" spread="9.76"/>
                    <measurement group_id="O3" value="72.67" spread="11.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min050</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.65" spread="7.52"/>
                    <measurement group_id="O2" value="76.47" spread="10.23"/>
                    <measurement group_id="O3" value="71.28" spread="10.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min060</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.88" spread="9.50"/>
                    <measurement group_id="O2" value="75.80" spread="9.30"/>
                    <measurement group_id="O3" value="71.94" spread="11.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min070</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.53" spread="11.21"/>
                    <measurement group_id="O2" value="75.27" spread="9.62"/>
                    <measurement group_id="O3" value="71.11" spread="12.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min080</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.41" spread="10.89"/>
                    <measurement group_id="O2" value="76.73" spread="9.80"/>
                    <measurement group_id="O3" value="71.61" spread="11.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min090</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.18" spread="11.48"/>
                    <measurement group_id="O2" value="74.53" spread="9.81"/>
                    <measurement group_id="O3" value="73.11" spread="14.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.29" spread="8.96"/>
                    <measurement group_id="O2" value="74.87" spread="7.74"/>
                    <measurement group_id="O3" value="73.94" spread="11.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min110</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.94" spread="6.97"/>
                    <measurement group_id="O2" value="77.07" spread="12.02"/>
                    <measurement group_id="O3" value="72.06" spread="12.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.94" spread="12.02"/>
                    <measurement group_id="O2" value="74.20" spread="8.94"/>
                    <measurement group_id="O3" value="72.28" spread="14.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min130</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.47" spread="8.87"/>
                    <measurement group_id="O2" value="76.27" spread="8.44"/>
                    <measurement group_id="O3" value="69.72" spread="13.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min140</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.94" spread="8.75"/>
                    <measurement group_id="O2" value="78.27" spread="8.96"/>
                    <measurement group_id="O3" value="71.06" spread="10.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min150</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.53" spread="6.38"/>
                    <measurement group_id="O2" value="75.60" spread="8.10"/>
                    <measurement group_id="O3" value="73.83" spread="11.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min160</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.88" spread="8.99"/>
                    <measurement group_id="O2" value="75.53" spread="17.01"/>
                    <measurement group_id="O3" value="72.22" spread="10.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min170</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.29" spread="6.28"/>
                    <measurement group_id="O2" value="74.40" spread="9.30"/>
                    <measurement group_id="O3" value="72.83" spread="11.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.06" spread="9.05"/>
                    <measurement group_id="O2" value="74.20" spread="9.67"/>
                    <measurement group_id="O3" value="72.22" spread="12.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min190</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.47" spread="9.41"/>
                    <measurement group_id="O2" value="74.67" spread="7.48"/>
                    <measurement group_id="O3" value="73.56" spread="11.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min200</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.18" spread="7.57"/>
                    <measurement group_id="O2" value="78.60" spread="9.83"/>
                    <measurement group_id="O3" value="74.33" spread="11.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min210</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.82" spread="9.51"/>
                    <measurement group_id="O2" value="76.20" spread="8.83"/>
                    <measurement group_id="O3" value="75.56" spread="11.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min220</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.47" spread="10.40"/>
                    <measurement group_id="O2" value="76.00" spread="9.06"/>
                    <measurement group_id="O3" value="75.17" spread="12.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min230</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.82" spread="9.13"/>
                    <measurement group_id="O2" value="76.40" spread="7.95"/>
                    <measurement group_id="O3" value="74.17" spread="9.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min240</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.47" spread="8.46"/>
                    <measurement group_id="O2" value="76.53" spread="7.79"/>
                    <measurement group_id="O3" value="74.00" spread="10.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min000</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.56" spread="8.69"/>
                    <measurement group_id="O2" value="77.50" spread="8.40"/>
                    <measurement group_id="O3" value="74.67" spread="11.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min005</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.17" spread="9.67"/>
                    <measurement group_id="O2" value="76.40" spread="8.49"/>
                    <measurement group_id="O3" value="76.18" spread="9.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min010</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.78" spread="9.90"/>
                    <measurement group_id="O2" value="78.07" spread="9.03"/>
                    <measurement group_id="O3" value="75.56" spread="13.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min015</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.00" spread="10.84"/>
                    <measurement group_id="O2" value="76.20" spread="9.65"/>
                    <measurement group_id="O3" value="75.78" spread="11.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min020</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.72" spread="11.10"/>
                    <measurement group_id="O2" value="77.80" spread="12.25"/>
                    <measurement group_id="O3" value="75.61" spread="12.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min025</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.72" spread="11.40"/>
                    <measurement group_id="O2" value="78.87" spread="10.80"/>
                    <measurement group_id="O3" value="77.06" spread="10.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min030</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.67" spread="9.00"/>
                    <measurement group_id="O2" value="78.81" spread="9.70"/>
                    <measurement group_id="O3" value="75.33" spread="11.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min040</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.06" spread="11.43"/>
                    <measurement group_id="O2" value="77.53" spread="10.85"/>
                    <measurement group_id="O3" value="75.89" spread="11.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min050</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.56" spread="10.78"/>
                    <measurement group_id="O2" value="78.40" spread="7.27"/>
                    <measurement group_id="O3" value="75.17" spread="11.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min060</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.83" spread="10.44"/>
                    <measurement group_id="O2" value="79.33" spread="11.17"/>
                    <measurement group_id="O3" value="74.61" spread="10.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min070</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.22" spread="10.33"/>
                    <measurement group_id="O2" value="78.13" spread="7.49"/>
                    <measurement group_id="O3" value="75.28" spread="9.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min080</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.89" spread="10.02"/>
                    <measurement group_id="O2" value="76.60" spread="7.49"/>
                    <measurement group_id="O3" value="75.06" spread="13.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min090</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.89" spread="7.08"/>
                    <measurement group_id="O2" value="79.07" spread="9.06"/>
                    <measurement group_id="O3" value="74.44" spread="10.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.50" spread="9.24"/>
                    <measurement group_id="O2" value="76.80" spread="10.75"/>
                    <measurement group_id="O3" value="73.56" spread="10.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min110</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.61" spread="8.13"/>
                    <measurement group_id="O2" value="76.53" spread="10.64"/>
                    <measurement group_id="O3" value="74.22" spread="9.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.61" spread="9.86"/>
                    <measurement group_id="O2" value="78.27" spread="8.40"/>
                    <measurement group_id="O3" value="75.89" spread="8.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Systolic Blood Pressure Per Infusion Phase by Group</title>
        <description>Infusion 2 (Day 14) - Systolic Blood Pressure at all time points by group
&quot;Phase&quot; in this analysis refers to the infusion stage as defined in the protocol.</description>
        <time_frame>Day 14 - Phase 1 - Baseline = min000s1 and @5 min; Phase 2 - Baseline = min000 then every 10 minutes for 4 hours; Post Infusion - Baseline = min000, then every 10 minutes for 2 hours</time_frame>
        <population>Includes all subjects during Phase 2 (i.e., infusion 2)</population>
        <group_list>
          <group group_id="O1">
            <title>Drug-Drug</title>
            <description>Phase 1 - intravenous sodium nitroprusside Phase 2 - intravenous sodium nitroprusside
sodium nitroprusside: intravenous</description>
          </group>
          <group group_id="O2">
            <title>Placebo-Drug</title>
            <description>Phase 1 - intravenous dextrose Phase 2 - intravenous sodium nitroprusside</description>
          </group>
          <group group_id="O3">
            <title>Placebo - Placebo</title>
            <description>Phase 1 - intravenous dextrose Phase 2 - intravenous dextrose
Placebo:</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure Per Infusion Phase by Group</title>
          <description>Infusion 2 (Day 14) - Systolic Blood Pressure at all time points by group
&quot;Phase&quot; in this analysis refers to the infusion stage as defined in the protocol.</description>
          <population>Includes all subjects during Phase 2 (i.e., infusion 2)</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phase 1 - min000s1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.69" spread="11.84"/>
                    <measurement group_id="O2" value="121.92" spread="9.66"/>
                    <measurement group_id="O3" value="122.61" spread="10.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 1 - min005s1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.69" spread="12.38"/>
                    <measurement group_id="O2" value="120.77" spread="12.38"/>
                    <measurement group_id="O3" value="119.39" spread="10.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min000</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.88" spread="11.61"/>
                    <measurement group_id="O2" value="120.92" spread="14.20"/>
                    <measurement group_id="O3" value="120.78" spread="12.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min005</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.50" spread="11.36"/>
                    <measurement group_id="O2" value="116.31" spread="9.96"/>
                    <measurement group_id="O3" value="120.39" spread="12.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min010</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.50" spread="9.39"/>
                    <measurement group_id="O2" value="113.38" spread="12.53"/>
                    <measurement group_id="O3" value="120.41" spread="12.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min015</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.88" spread="9.06"/>
                    <measurement group_id="O2" value="113.46" spread="10.32"/>
                    <measurement group_id="O3" value="117.28" spread="13.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min020</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.19" spread="8.93"/>
                    <measurement group_id="O2" value="112.62" spread="10.66"/>
                    <measurement group_id="O3" value="117.94" spread="12.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min025</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.81" spread="11.11"/>
                    <measurement group_id="O2" value="115.62" spread="13.88"/>
                    <measurement group_id="O3" value="118.22" spread="14.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min030</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.88" spread="8.43"/>
                    <measurement group_id="O2" value="113.69" spread="16.09"/>
                    <measurement group_id="O3" value="116.44" spread="13.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min040</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.06" spread="8.46"/>
                    <measurement group_id="O2" value="117.54" spread="16.58"/>
                    <measurement group_id="O3" value="118.94" spread="11.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min050</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.00" spread="10.22"/>
                    <measurement group_id="O2" value="112.77" spread="13.91"/>
                    <measurement group_id="O3" value="118.56" spread="15.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min060</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.63" spread="13.20"/>
                    <measurement group_id="O2" value="113.31" spread="14.12"/>
                    <measurement group_id="O3" value="116.94" spread="12.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min070</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.56" spread="10.46"/>
                    <measurement group_id="O2" value="113.15" spread="12.15"/>
                    <measurement group_id="O3" value="118.50" spread="14.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min080</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.50" spread="10.98"/>
                    <measurement group_id="O2" value="113.08" spread="15.34"/>
                    <measurement group_id="O3" value="118.50" spread="13.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min090</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.06" spread="10.59"/>
                    <measurement group_id="O2" value="109.00" spread="11.63"/>
                    <measurement group_id="O3" value="118.06" spread="12.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106.94" spread="11.58"/>
                    <measurement group_id="O2" value="111.50" spread="16.10"/>
                    <measurement group_id="O3" value="119.00" spread="14.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min110</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.67" spread="7.80"/>
                    <measurement group_id="O2" value="112.46" spread="16.04"/>
                    <measurement group_id="O3" value="120.39" spread="11.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.87" spread="9.19"/>
                    <measurement group_id="O2" value="106.33" spread="10.87"/>
                    <measurement group_id="O3" value="118.83" spread="15.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min130</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.53" spread="10.70"/>
                    <measurement group_id="O2" value="110.17" spread="11.75"/>
                    <measurement group_id="O3" value="120.06" spread="13.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min140</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.27" spread="10.50"/>
                    <measurement group_id="O2" value="110.54" spread="11.23"/>
                    <measurement group_id="O3" value="120.33" spread="15.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min150</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.13" spread="11.42"/>
                    <measurement group_id="O2" value="110.83" spread="18.52"/>
                    <measurement group_id="O3" value="117.67" spread="12.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min160</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.87" spread="11.11"/>
                    <measurement group_id="O2" value="116.17" spread="13.07"/>
                    <measurement group_id="O3" value="121.17" spread="13.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min170</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.33" spread="12.61"/>
                    <measurement group_id="O2" value="113.33" spread="12.04"/>
                    <measurement group_id="O3" value="120.61" spread="12.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.27" spread="9.38"/>
                    <measurement group_id="O2" value="113.92" spread="11.77"/>
                    <measurement group_id="O3" value="117.67" spread="11.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min190</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.47" spread="9.82"/>
                    <measurement group_id="O2" value="114.83" spread="16.46"/>
                    <measurement group_id="O3" value="120.72" spread="11.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min200</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.40" spread="13.47"/>
                    <measurement group_id="O2" value="115.08" spread="16.76"/>
                    <measurement group_id="O3" value="120.94" spread="14.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min210</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.13" spread="14.71"/>
                    <measurement group_id="O2" value="114.33" spread="17.85"/>
                    <measurement group_id="O3" value="121.17" spread="11.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min220</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.20" spread="15.18"/>
                    <measurement group_id="O2" value="112.33" spread="11.54"/>
                    <measurement group_id="O3" value="120.06" spread="11.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min230</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.27" spread="12.79"/>
                    <measurement group_id="O2" value="113.58" spread="12.92"/>
                    <measurement group_id="O3" value="118.83" spread="12.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min240</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.53" spread="9.48"/>
                    <measurement group_id="O2" value="111.83" spread="12.58"/>
                    <measurement group_id="O3" value="119.00" spread="12.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min000</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.75" spread="9.94"/>
                    <measurement group_id="O2" value="113.25" spread="13.51"/>
                    <measurement group_id="O3" value="118.22" spread="120.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min005</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.06" spread="12.41"/>
                    <measurement group_id="O2" value="118.25" spread="18.23"/>
                    <measurement group_id="O3" value="120.28" spread="11.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min010</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.88" spread="16.70"/>
                    <measurement group_id="O2" value="122.83" spread="16.03"/>
                    <measurement group_id="O3" value="122.94" spread="10.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min015</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.75" spread="15.07"/>
                    <measurement group_id="O2" value="124.58" spread="16.14"/>
                    <measurement group_id="O3" value="122.78" spread="11.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min020</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.00" spread="11.55"/>
                    <measurement group_id="O2" value="122.92" spread="13.24"/>
                    <measurement group_id="O3" value="121.56" spread="12.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min025</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.00" spread="12.41"/>
                    <measurement group_id="O2" value="125.83" spread="16.94"/>
                    <measurement group_id="O3" value="126.67" spread="15.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min030</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.50" spread="12.56"/>
                    <measurement group_id="O2" value="123.67" spread="16.54"/>
                    <measurement group_id="O3" value="126.06" spread="14.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min040</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.44" spread="11.40"/>
                    <measurement group_id="O2" value="123.92" spread="11.24"/>
                    <measurement group_id="O3" value="122.11" spread="13.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min050</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.75" spread="22.66"/>
                    <measurement group_id="O2" value="124.17" spread="13.19"/>
                    <measurement group_id="O3" value="122.72" spread="14.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min060</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125.31" spread="14.93"/>
                    <measurement group_id="O2" value="121.08" spread="12.45"/>
                    <measurement group_id="O3" value="123.17" spread="15.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min070</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.44" spread="19.68"/>
                    <measurement group_id="O2" value="120.33" spread="10.46"/>
                    <measurement group_id="O3" value="124.78" spread="14.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min080</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.38" spread="15.21"/>
                    <measurement group_id="O2" value="121.83" spread="14.65"/>
                    <measurement group_id="O3" value="123.17" spread="13.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min090</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.25" spread="14.19"/>
                    <measurement group_id="O2" value="125.08" spread="13.73"/>
                    <measurement group_id="O3" value="126.28" spread="14.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.94" spread="21.68"/>
                    <measurement group_id="O2" value="123.92" spread="10.99"/>
                    <measurement group_id="O3" value="122.94" spread="16.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min110</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.50" spread="13.57"/>
                    <measurement group_id="O2" value="125.17" spread="16.51"/>
                    <measurement group_id="O3" value="125.06" spread="11.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.31" spread="16.41"/>
                    <measurement group_id="O2" value="125.75" spread="12.26"/>
                    <measurement group_id="O3" value="125.00" spread="12.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Phase 2 - Diastolic Blood Pressure Per Infusion Phase by Group</title>
        <description>Infusion 2 (Day 14) - Diastolic Blood Pressure at all time points by group</description>
        <time_frame>Day 14 - Phase 1 - Baseline = min000s1 and @5 min; Phase 2 - Baseline = min000 then every 10 minutes for 4 hours; Post Infusion - Baseline = min000, then every 10 minutes for 2 hours</time_frame>
        <population>Includes all subjects during Phase 1 (i.e., infusion 1)</population>
        <group_list>
          <group group_id="O1">
            <title>Drug-Drug</title>
            <description>Phase 1 - intravenous sodium nitroprusside Phase 2 - intravenous sodium nitroprusside
sodium nitroprusside: intravenous</description>
          </group>
          <group group_id="O2">
            <title>Placebo-Drug</title>
            <description>Phase 1 - intravenous dextrose Phase 2 - intravenous sodium nitroprusside</description>
          </group>
          <group group_id="O3">
            <title>Placebo - Placebo</title>
            <description>Phase 1 - intravenous dextrose Phase 2 - intravenous dextrose
Placebo:</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 2 - Diastolic Blood Pressure Per Infusion Phase by Group</title>
          <description>Infusion 2 (Day 14) - Diastolic Blood Pressure at all time points by group</description>
          <population>Includes all subjects during Phase 1 (i.e., infusion 1)</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phase 1 - min000s1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.38" spread="7.80"/>
                    <measurement group_id="O2" value="74.50" spread="8.89"/>
                    <measurement group_id="O3" value="74.50" spread="8.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 1 - min005s1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.56" spread="8.78"/>
                    <measurement group_id="O2" value="73.89" spread="8.70"/>
                    <measurement group_id="O3" value="73.89" spread="8.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min000</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.94" spread="8.46"/>
                    <measurement group_id="O2" value="72.72" spread="8.84"/>
                    <measurement group_id="O3" value="72.72" spread="8.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min005</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.00" spread="6.23"/>
                    <measurement group_id="O2" value="71.28" spread="7.28"/>
                    <measurement group_id="O3" value="71.28" spread="7.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min010</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.63" spread="7.57"/>
                    <measurement group_id="O2" value="74.65" spread="9.03"/>
                    <measurement group_id="O3" value="74.65" spread="9.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min015</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.44" spread="9.06"/>
                    <measurement group_id="O2" value="73.50" spread="7.15"/>
                    <measurement group_id="O3" value="73.50" spread="7.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min020</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.19" spread="8.72"/>
                    <measurement group_id="O2" value="70.94" spread="7.07"/>
                    <measurement group_id="O3" value="70.94" spread="7.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min025</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.25" spread="8.29"/>
                    <measurement group_id="O2" value="71.56" spread="9.10"/>
                    <measurement group_id="O3" value="71.56" spread="9.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min030</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.75" spread="7.87"/>
                    <measurement group_id="O2" value="71.11" spread="7.23"/>
                    <measurement group_id="O3" value="71.11" spread="7.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min040</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.94" spread="8.82"/>
                    <measurement group_id="O2" value="73.17" spread="9.07"/>
                    <measurement group_id="O3" value="73.17" spread="9.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min050</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.25" spread="8.42"/>
                    <measurement group_id="O2" value="71.89" spread="12.07"/>
                    <measurement group_id="O3" value="71.89" spread="12.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min060</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.38" spread="11.97"/>
                    <measurement group_id="O2" value="71.44" spread="12.23"/>
                    <measurement group_id="O3" value="71.44" spread="12.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min070</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.19" spread="10.78"/>
                    <measurement group_id="O2" value="71.00" spread="10.77"/>
                    <measurement group_id="O3" value="71.00" spread="10.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min080</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.00" spread="7.38"/>
                    <measurement group_id="O2" value="70.72" spread="12.81"/>
                    <measurement group_id="O3" value="70.72" spread="12.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min090</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.13" spread="7.83"/>
                    <measurement group_id="O2" value="70.22" spread="12.34"/>
                    <measurement group_id="O3" value="70.22" spread="12.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.13" spread="8.37"/>
                    <measurement group_id="O2" value="71.00" spread="12.39"/>
                    <measurement group_id="O3" value="71.00" spread="12.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min110</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.73" spread="5.97"/>
                    <measurement group_id="O2" value="71.89" spread="11.54"/>
                    <measurement group_id="O3" value="71.89" spread="11.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.47" spread="8.59"/>
                    <measurement group_id="O2" value="68.28" spread="10.65"/>
                    <measurement group_id="O3" value="68.28" spread="10.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min130</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.33" spread="8.16"/>
                    <measurement group_id="O2" value="73.44" spread="11.94"/>
                    <measurement group_id="O3" value="73.44" spread="11.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min140</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.73" spread="10.23"/>
                    <measurement group_id="O2" value="71.56" spread="10.87"/>
                    <measurement group_id="O3" value="71.56" spread="10.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min150</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.87" spread="10.10"/>
                    <measurement group_id="O2" value="74.06" spread="12.80"/>
                    <measurement group_id="O3" value="74.06" spread="12.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min160</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.53" spread="7.68"/>
                    <measurement group_id="O2" value="73.94" spread="10.41"/>
                    <measurement group_id="O3" value="73.94" spread="10.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min170</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.87" spread="11.60"/>
                    <measurement group_id="O2" value="74.61" spread="8.43"/>
                    <measurement group_id="O3" value="74.61" spread="8.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.27" spread="9.00"/>
                    <measurement group_id="O2" value="72.28" spread="8.17"/>
                    <measurement group_id="O3" value="72.28" spread="8.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min190</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.73" spread="10.23"/>
                    <measurement group_id="O2" value="73.00" spread="10.99"/>
                    <measurement group_id="O3" value="73.00" spread="10.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min200</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.40" spread="7.03"/>
                    <measurement group_id="O2" value="73.56" spread="10.35"/>
                    <measurement group_id="O3" value="73.56" spread="10.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min210</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.27" spread="9.00"/>
                    <measurement group_id="O2" value="74.11" spread="11.53"/>
                    <measurement group_id="O3" value="74.11" spread="11.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min220</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.13" spread="8.60"/>
                    <measurement group_id="O2" value="72.22" spread="9.62"/>
                    <measurement group_id="O3" value="72.22" spread="9.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min230</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.00" spread="8.12"/>
                    <measurement group_id="O2" value="72.33" spread="10.48"/>
                    <measurement group_id="O3" value="72.33" spread="10.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min240</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.60" spread="8.58"/>
                    <measurement group_id="O2" value="70.11" spread="8.05"/>
                    <measurement group_id="O3" value="70.11" spread="8.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min000</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.81" spread="8.42"/>
                    <measurement group_id="O2" value="70.39" spread="8.10"/>
                    <measurement group_id="O3" value="70.39" spread="8.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min005</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.31" spread="7.87"/>
                    <measurement group_id="O2" value="71.94" spread="9.14"/>
                    <measurement group_id="O3" value="71.94" spread="9.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min010</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.06" spread="9.26"/>
                    <measurement group_id="O2" value="73.39" spread="9.76"/>
                    <measurement group_id="O3" value="73.39" spread="9.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min015</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.13" spread="10.20"/>
                    <measurement group_id="O2" value="75.67" spread="10.79"/>
                    <measurement group_id="O3" value="75.67" spread="10.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min020</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.44" spread="12.44"/>
                    <measurement group_id="O2" value="74.89" spread="9.62"/>
                    <measurement group_id="O3" value="74.89" spread="8.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min025</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.88" spread="12.94"/>
                    <measurement group_id="O2" value="76.89" spread="8.66"/>
                    <measurement group_id="O3" value="76.89" spread="8.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min030</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.81" spread="12.45"/>
                    <measurement group_id="O2" value="76.89" spread="14.57"/>
                    <measurement group_id="O3" value="76.89" spread="14.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min040</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.31" spread="14.89"/>
                    <measurement group_id="O2" value="72.39" spread="11.32"/>
                    <measurement group_id="O3" value="72.39" spread="11.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min050</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.25" spread="10.79"/>
                    <measurement group_id="O2" value="74.72" spread="12.56"/>
                    <measurement group_id="O3" value="74.72" spread="12.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min060</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.69" spread="7.88"/>
                    <measurement group_id="O2" value="74.11" spread="11.90"/>
                    <measurement group_id="O3" value="74.11" spread="11.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min070</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.81" spread="9.72"/>
                    <measurement group_id="O2" value="76.78" spread="10.28"/>
                    <measurement group_id="O3" value="76.78" spread="10.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min080</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.88" spread="7.87"/>
                    <measurement group_id="O2" value="74.61" spread="11.25"/>
                    <measurement group_id="O3" value="74.61" spread="11.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min090</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.88" spread="8.87"/>
                    <measurement group_id="O2" value="73.83" spread="11.40"/>
                    <measurement group_id="O3" value="73.83" spread="11.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.38" spread="8.61"/>
                    <measurement group_id="O2" value="74.28" spread="12.15"/>
                    <measurement group_id="O3" value="74.28" spread="12.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min110</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.81" spread="9.09"/>
                    <measurement group_id="O2" value="77.11" spread="10.78"/>
                    <measurement group_id="O3" value="77.11" spread="10.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.56" spread="7.69"/>
                    <measurement group_id="O2" value="78.00" spread="9.15"/>
                    <measurement group_id="O3" value="78.00" spread="9.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Heart Rate Per Infusion Phase by Group</title>
        <description>Infusion 1 (Day 0) - Heart rate at all time points by group
&quot;Phase&quot; in this analysis refers to the infusion stage as defined in the protocol.</description>
        <time_frame>Day 0 - Phase 1 - Baseline = min000s1 and @5 min; Phase 2 - Baseline = min000 then every 10 minutes for 4 hours; Post Infusion - Baseline = min000, then every 10 minutes for 2 hours</time_frame>
        <population>Includes all subjects during Phase 1 (i.e., infusion 1)</population>
        <group_list>
          <group group_id="O1">
            <title>Drug-Drug</title>
            <description>Phase 1 - intravenous sodium nitroprusside Phase 2 - intravenous sodium nitroprusside
sodium nitroprusside: intravenous</description>
          </group>
          <group group_id="O2">
            <title>Placebo-Drug</title>
            <description>Phase 1 - intravenous dextrose Phase 2 - intravenous sodium nitroprusside</description>
          </group>
          <group group_id="O3">
            <title>Placebo - Placebo</title>
            <description>Phase 1 - intravenous dextrose Phase 2 - intravenous dextrose
Placebo:</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate Per Infusion Phase by Group</title>
          <description>Infusion 1 (Day 0) - Heart rate at all time points by group
&quot;Phase&quot; in this analysis refers to the infusion stage as defined in the protocol.</description>
          <population>Includes all subjects during Phase 1 (i.e., infusion 1)</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phase 1 - min000s1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.47" spread="13.11"/>
                    <measurement group_id="O2" value="79.00" spread="15.84"/>
                    <measurement group_id="O3" value="79.94" spread="17.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 1 - min005s1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.21" spread="15.79"/>
                    <measurement group_id="O2" value="77.81" spread="14.39"/>
                    <measurement group_id="O3" value="79.44" spread="16.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min000</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.00" spread="13.81"/>
                    <measurement group_id="O2" value="76.94" spread="15.05"/>
                    <measurement group_id="O3" value="79.94" spread="16.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min005</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.47" spread="13.49"/>
                    <measurement group_id="O2" value="77.88" spread="15.13"/>
                    <measurement group_id="O3" value="78.00" spread="17.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min010</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.17" spread="13.44"/>
                    <measurement group_id="O2" value="77.25" spread="14.75"/>
                    <measurement group_id="O3" value="79.61" spread="16.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min015</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.33" spread="13.97"/>
                    <measurement group_id="O2" value="78.00" spread="14.01"/>
                    <measurement group_id="O3" value="77.89" spread="17.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min020</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.00" spread="13.84"/>
                    <measurement group_id="O2" value="76.44" spread="14.77"/>
                    <measurement group_id="O3" value="79.28" spread="17.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min025</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.83" spread="14.61"/>
                    <measurement group_id="O2" value="77.13" spread="13.61"/>
                    <measurement group_id="O3" value="77.06" spread="17.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min030</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.94" spread="14.21"/>
                    <measurement group_id="O2" value="76.69" spread="14.38"/>
                    <measurement group_id="O3" value="78.83" spread="17.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min040</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.06" spread="13.98"/>
                    <measurement group_id="O2" value="77.88" spread="14.42"/>
                    <measurement group_id="O3" value="77.56" spread="18.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min050</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.65" spread="14.28"/>
                    <measurement group_id="O2" value="76.67" spread="13.28"/>
                    <measurement group_id="O3" value="79.50" spread="18.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min060</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.59" spread="13.86"/>
                    <measurement group_id="O2" value="78.13" spread="12.88"/>
                    <measurement group_id="O3" value="78.56" spread="17.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min070</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.53" spread="13.73"/>
                    <measurement group_id="O2" value="77.07" spread="12.66"/>
                    <measurement group_id="O3" value="77.11" spread="17.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min080</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.76" spread="13.37"/>
                    <measurement group_id="O2" value="76.47" spread="15.08"/>
                    <measurement group_id="O3" value="76.89" spread="17.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min090</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.82" spread="12.73"/>
                    <measurement group_id="O2" value="77.80" spread="14.36"/>
                    <measurement group_id="O3" value="76.22" spread="17.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.29" spread="12.46"/>
                    <measurement group_id="O2" value="78.53" spread="12.82"/>
                    <measurement group_id="O3" value="75.94" spread="16.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min110</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.18" spread="12.54"/>
                    <measurement group_id="O2" value="76.73" spread="11.66"/>
                    <measurement group_id="O3" value="75.44" spread="16.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.71" spread="11.97"/>
                    <measurement group_id="O2" value="78.47" spread="13.52"/>
                    <measurement group_id="O3" value="78.39" spread="20.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min130</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.59" spread="12.50"/>
                    <measurement group_id="O2" value="77.33" spread="12.66"/>
                    <measurement group_id="O3" value="75.94" spread="15.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min140</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.76" spread="11.99"/>
                    <measurement group_id="O2" value="77.60" spread="12.79"/>
                    <measurement group_id="O3" value="75.28" spread="16.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min150</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.06" spread="13.38"/>
                    <measurement group_id="O2" value="79.67" spread="11.79"/>
                    <measurement group_id="O3" value="76.06" spread="15.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min160</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.41" spread="11.49"/>
                    <measurement group_id="O2" value="78.73" spread="11.81"/>
                    <measurement group_id="O3" value="79.33" spread="16.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min170</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.88" spread="11.19"/>
                    <measurement group_id="O2" value="79.07" spread="13.57"/>
                    <measurement group_id="O3" value="76.44" spread="18.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.12" spread="10.34"/>
                    <measurement group_id="O2" value="77.53" spread="13.72"/>
                    <measurement group_id="O3" value="78.56" spread="16.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min190</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.24" spread="12.40"/>
                    <measurement group_id="O2" value="79.40" spread="15.08"/>
                    <measurement group_id="O3" value="76.89" spread="16.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min200</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.41" spread="11.37"/>
                    <measurement group_id="O2" value="79.27" spread="13.42"/>
                    <measurement group_id="O3" value="80.00" spread="15.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min210</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.24" spread="11.68"/>
                    <measurement group_id="O2" value="80.27" spread="14.39"/>
                    <measurement group_id="O3" value="77.50" spread="15.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min220</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.94" spread="12.29"/>
                    <measurement group_id="O2" value="79.93" spread="14.10"/>
                    <measurement group_id="O3" value="77.33" spread="16.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min230</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.47" spread="12.96"/>
                    <measurement group_id="O2" value="79.87" spread="15.06"/>
                    <measurement group_id="O3" value="78.78" spread="16.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min240</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.29" spread="12.01"/>
                    <measurement group_id="O2" value="79.40" spread="13.74"/>
                    <measurement group_id="O3" value="78.56" spread="16.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min000</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.28" spread="11.96"/>
                    <measurement group_id="O2" value="82.44" spread="14.81"/>
                    <measurement group_id="O3" value="78.11" spread="16.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min005</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.39" spread="12.46"/>
                    <measurement group_id="O2" value="80.80" spread="15.81"/>
                    <measurement group_id="O3" value="80.29" spread="16.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min010</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.78" spread="12.74"/>
                    <measurement group_id="O2" value="78.67" spread="1317"/>
                    <measurement group_id="O3" value="78.83" spread="14.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min015</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.67" spread="10.32"/>
                    <measurement group_id="O2" value="79.93" spread="13.34"/>
                    <measurement group_id="O3" value="79.39" spread="15.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min020</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.06" spread="10.78"/>
                    <measurement group_id="O2" value="82.13" spread="13.91"/>
                    <measurement group_id="O3" value="80.33" spread="16.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min025</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.78" spread="11.83"/>
                    <measurement group_id="O2" value="81.60" spread="13.83"/>
                    <measurement group_id="O3" value="78.22" spread="17.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min030</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.39" spread="13.56"/>
                    <measurement group_id="O2" value="82.13" spread="13.07"/>
                    <measurement group_id="O3" value="79.72" spread="16.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min040</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.72" spread="12.55"/>
                    <measurement group_id="O2" value="81.47" spread="13.41"/>
                    <measurement group_id="O3" value="78.72" spread="15.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min050</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.06" spread="12.32"/>
                    <measurement group_id="O2" value="78.47" spread="13.45"/>
                    <measurement group_id="O3" value="81.28" spread="15.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min060</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.17" spread="11.93"/>
                    <measurement group_id="O2" value="79.40" spread="12.40"/>
                    <measurement group_id="O3" value="78.83" spread="15.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min070</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.83" spread="10.74"/>
                    <measurement group_id="O2" value="81.87" spread="15.81"/>
                    <measurement group_id="O3" value="79.94" spread="14.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min080</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.44" spread="10.92"/>
                    <measurement group_id="O2" value="83.87" spread="11.54"/>
                    <measurement group_id="O3" value="80.33" spread="16.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min090</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.11" spread="12.36"/>
                    <measurement group_id="O2" value="82.33" spread="12.82"/>
                    <measurement group_id="O3" value="79.22" spread="17.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.17" spread="12.66"/>
                    <measurement group_id="O2" value="84.67" spread="12.58"/>
                    <measurement group_id="O3" value="80.00" spread="16.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min110</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.67" spread="11.74"/>
                    <measurement group_id="O2" value="82.80" spread="13.61"/>
                    <measurement group_id="O3" value="80.61" spread="16.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.56" spread="11.98"/>
                    <measurement group_id="O2" value="83.47" spread="13.44"/>
                    <measurement group_id="O3" value="80.00" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Heart Rate Per Infusion Phase by Group</title>
        <description>Infusion 2 (Day 14) - Heart rate at all time points by group
&quot;Phase&quot; in this analysis refers to the infusion stage as defined in the protocol.</description>
        <time_frame>Day 14 - Phase 1 - Baseline = min000s1 and @5 min; Phase 2 - Baseline = min000 then every 10 minutes for 4 hours; Post Infusion - Baseline = min000, then every 10 minutes for 2 hours</time_frame>
        <population>Includes all subjects during Phase 1 (i.e., infusion 1)</population>
        <group_list>
          <group group_id="O1">
            <title>Drug-Drug</title>
            <description>Phase 1 - intravenous sodium nitroprusside Phase 2 - intravenous sodium nitroprusside
sodium nitroprusside: intravenous</description>
          </group>
          <group group_id="O2">
            <title>Placebo-Drug</title>
            <description>Phase 1 - intravenous dextrose Phase 2 - intravenous sodium nitroprusside</description>
          </group>
          <group group_id="O3">
            <title>Placebo - Placebo</title>
            <description>Phase 1 - intravenous dextrose Phase 2 - intravenous dextrose
Placebo:</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate Per Infusion Phase by Group</title>
          <description>Infusion 2 (Day 14) - Heart rate at all time points by group
&quot;Phase&quot; in this analysis refers to the infusion stage as defined in the protocol.</description>
          <population>Includes all subjects during Phase 1 (i.e., infusion 1)</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phase 1 - min000s1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.38" spread="11.77"/>
                    <measurement group_id="O2" value="75.08" spread="13.94"/>
                    <measurement group_id="O3" value="76.94" spread="18.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 1 - min005s1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.69" spread="12.43"/>
                    <measurement group_id="O2" value="76.77" spread="14.86"/>
                    <measurement group_id="O3" value="78.67" spread="17.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min000</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.06" spread="11.25"/>
                    <measurement group_id="O2" value="77.77" spread="15.24"/>
                    <measurement group_id="O3" value="78.72" spread="17.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min005</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.31" spread="12.88"/>
                    <measurement group_id="O2" value="81.38" spread="15.32"/>
                    <measurement group_id="O3" value="76.39" spread="17.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min010</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.50" spread="13.46"/>
                    <measurement group_id="O2" value="80.62" spread="16.44"/>
                    <measurement group_id="O3" value="77.12" spread="17.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min015</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.38" spread="12.99"/>
                    <measurement group_id="O2" value="80.92" spread="15.40"/>
                    <measurement group_id="O3" value="76.06" spread="17.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min020</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.06" spread="12.13"/>
                    <measurement group_id="O2" value="79.69" spread="16.73"/>
                    <measurement group_id="O3" value="74.89" spread="16.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min025</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.31" spread="12.35"/>
                    <measurement group_id="O2" value="80.69" spread="18.08"/>
                    <measurement group_id="O3" value="76.22" spread="16.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min030</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.50" spread="10.22"/>
                    <measurement group_id="O2" value="81.15" spread="16.32"/>
                    <measurement group_id="O3" value="76.17" spread="15.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min040</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.88" spread="13.61"/>
                    <measurement group_id="O2" value="81.69" spread="15.50"/>
                    <measurement group_id="O3" value="76.72" spread="15.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min050</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.25" spread="12.23"/>
                    <measurement group_id="O2" value="78.85" spread="15.42"/>
                    <measurement group_id="O3" value="75.00" spread="16.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min060</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.69" spread="15.12"/>
                    <measurement group_id="O2" value="79.69" spread="14.63"/>
                    <measurement group_id="O3" value="75.50" spread="15.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min070</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.69" spread="13.85"/>
                    <measurement group_id="O2" value="81.31" spread="13.53"/>
                    <measurement group_id="O3" value="75.06" spread="16.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min080</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.44" spread="13.93"/>
                    <measurement group_id="O2" value="80.23" spread="14.11"/>
                    <measurement group_id="O3" value="75.39" spread="14.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min090</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.00" spread="14.58"/>
                    <measurement group_id="O2" value="79.58" spread="14.71"/>
                    <measurement group_id="O3" value="73.78" spread="15.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.94" spread="14.29"/>
                    <measurement group_id="O2" value="78.17" spread="14.66"/>
                    <measurement group_id="O3" value="76.11" spread="15.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min110</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.33" spread="11.58"/>
                    <measurement group_id="O2" value="80.15" spread="15.51"/>
                    <measurement group_id="O3" value="75.17" spread="15.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.47" spread="12.97"/>
                    <measurement group_id="O2" value="81.25" spread="16.16"/>
                    <measurement group_id="O3" value="74.56" spread="14.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min130</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.13" spread="13.03"/>
                    <measurement group_id="O2" value="78.75" spread="15.24"/>
                    <measurement group_id="O3" value="75.11" spread="13.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min140</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.73" spread="13.95"/>
                    <measurement group_id="O2" value="80.69" spread="14.92"/>
                    <measurement group_id="O3" value="75.89" spread="15.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min150</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.40" spread="12.57"/>
                    <measurement group_id="O2" value="78.75" spread="13.59"/>
                    <measurement group_id="O3" value="75.78" spread="14.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min160</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.53" spread="13.20"/>
                    <measurement group_id="O2" value="80.00" spread="11.26"/>
                    <measurement group_id="O3" value="75.33" spread="13.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min170</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.60" spread="14.46"/>
                    <measurement group_id="O2" value="78.75" spread="12.55"/>
                    <measurement group_id="O3" value="75.06" spread="14.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.00" spread="12.91"/>
                    <measurement group_id="O2" value="81.25" spread="12.81"/>
                    <measurement group_id="O3" value="74.78" spread="14.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min190</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.93" spread="12.91"/>
                    <measurement group_id="O2" value="80.58" spread="16.37"/>
                    <measurement group_id="O3" value="73.94" spread="14.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min200</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.60" spread="14.39"/>
                    <measurement group_id="O2" value="80.33" spread="14.27"/>
                    <measurement group_id="O3" value="75.00" spread="12.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min210</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.73" spread="11.93"/>
                    <measurement group_id="O2" value="80.75" spread="17.12"/>
                    <measurement group_id="O3" value="75.33" spread="15.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min220</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.07" spread="12.55"/>
                    <measurement group_id="O2" value="79.92" spread="13.92"/>
                    <measurement group_id="O3" value="74.61" spread="14.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min230</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.07" spread="11.78"/>
                    <measurement group_id="O2" value="78.00" spread="14.59"/>
                    <measurement group_id="O3" value="77.56" spread="14.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phase 2 - min240</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.53" spread="13.73"/>
                    <measurement group_id="O2" value="80.42" spread="12.55"/>
                    <measurement group_id="O3" value="76.72" spread="15.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min000</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.50" spread="13.85"/>
                    <measurement group_id="O2" value="79.25" spread="14.77"/>
                    <measurement group_id="O3" value="76.22" spread="16.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min005</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.44" spread="12.19"/>
                    <measurement group_id="O2" value="73.25" spread="13.97"/>
                    <measurement group_id="O3" value="79.06" spread="16.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min010</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.38" spread="13.64"/>
                    <measurement group_id="O2" value="73.75" spread="13.60"/>
                    <measurement group_id="O3" value="77.78" spread="15.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min015</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.13" spread="13.59"/>
                    <measurement group_id="O2" value="75.17" spread="12.71"/>
                    <measurement group_id="O3" value="78.83" spread="14.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min020</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.88" spread="13.72"/>
                    <measurement group_id="O2" value="76.92" spread="11.24"/>
                    <measurement group_id="O3" value="78.39" spread="14.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min025</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.25" spread="12.46"/>
                    <measurement group_id="O2" value="75.75" spread="14.14"/>
                    <measurement group_id="O3" value="77.44" spread="12.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min030</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.31" spread="11.16"/>
                    <measurement group_id="O2" value="74.83" spread="11.76"/>
                    <measurement group_id="O3" value="78.33" spread="13.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min040</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.63" spread="16.66"/>
                    <measurement group_id="O2" value="74.92" spread="10.42"/>
                    <measurement group_id="O3" value="78.39" spread="13.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min050</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.00" spread="11.89"/>
                    <measurement group_id="O2" value="75.67" spread="12.20"/>
                    <measurement group_id="O3" value="78.33" spread="14.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min060</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.00" spread="11.35"/>
                    <measurement group_id="O2" value="77.08" spread="13.21"/>
                    <measurement group_id="O3" value="79.11" spread="13.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min070</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.81" spread="11.12"/>
                    <measurement group_id="O2" value="77.75" spread="13.92"/>
                    <measurement group_id="O3" value="77.50" spread="13.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min080</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.69" spread="10.87"/>
                    <measurement group_id="O2" value="75.92" spread="14.85"/>
                    <measurement group_id="O3" value="78.06" spread="14.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min090</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.25" spread="10.07"/>
                    <measurement group_id="O2" value="78.42" spread="16.55"/>
                    <measurement group_id="O3" value="78.89" spread="14.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.06" spread="10.51"/>
                    <measurement group_id="O2" value="79.75" spread="16.80"/>
                    <measurement group_id="O3" value="80.17" spread="14.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min110</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.88" spread="10.25"/>
                    <measurement group_id="O2" value="77.50" spread="16.94"/>
                    <measurement group_id="O3" value="80.22" spread="14.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Infusion - min120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.19" spread="11.73"/>
                    <measurement group_id="O2" value="80.83" spread="17.02"/>
                    <measurement group_id="O3" value="78.44" spread="14.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>ECG Measures at All Time Points by Group</title>
        <description>Infusion 1 (Day 0) - ECG measures at all time points by group</description>
        <time_frame>Day 0 - Baseline (pre-infusion), During Infusion (@30 min), Post-Infusion (@60min)</time_frame>
        <population>All subjects receiving a complete or partial Phase 1 infusion</population>
        <group_list>
          <group group_id="O1">
            <title>Drug - Drug</title>
            <description>Phase 1 - intravenous sodium Nitroprusside (Drug) Phase 2 - intravenous sodium Nitroprusside (Drug)
Subjects will receive i.v. sodium nitroprusside (0.5 μg/kg/min for 4 hours) at Day 0 (Phase 1) and Day 14 (Phase 2)</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Drug</title>
            <description>Phase 1 - intravenous dextrose (Placebo) Phase 2 - intravenous sodium Nitroprusside (Drug)
Subjects will receive i.v. placebo (intravenous dextrose) at Day 0 (Phase 1) and i.v. sodium nitroprusside (0.5 μg/kg/min for 4 hours) at Day 14 (Phase 2)</description>
          </group>
          <group group_id="O3">
            <title>Placebo - Placebo</title>
            <description>Phase 1 - intravenous dextrose (Placebo) Phase 2 - intravenous dextrose (Placebo)
Subjects will receive i.v. placebo (intravenous dextrose) at Day 0 (Phase 1) and again at Day 14 (Phase 2).</description>
          </group>
        </group_list>
        <measure>
          <title>ECG Measures at All Time Points by Group</title>
          <description>Infusion 1 (Day 0) - ECG measures at all time points by group</description>
          <population>All subjects receiving a complete or partial Phase 1 infusion</population>
          <units>mm/sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline_PR Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162.84" spread="30.09"/>
                    <measurement group_id="O2" value="149.11" spread="11.52"/>
                    <measurement group_id="O3" value="164.56" spread="19.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline_QRS Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.37" spread="11.37"/>
                    <measurement group_id="O2" value="86.89" spread="8.76"/>
                    <measurement group_id="O3" value="88.11" spread="10.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline_QT Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="380.16" spread="26.60"/>
                    <measurement group_id="O2" value="384.28" spread="31.47"/>
                    <measurement group_id="O3" value="381.94" spread="36.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline_RR Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" spread="0.19"/>
                    <measurement group_id="O2" value="0.82" spread="0.15"/>
                    <measurement group_id="O3" value="0.81" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30min_PR Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159.63" spread="34.81"/>
                    <measurement group_id="O2" value="152.40" spread="12.44"/>
                    <measurement group_id="O3" value="167.59" spread="21.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30min_QRS Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.79" spread="11.22"/>
                    <measurement group_id="O2" value="88.00" spread="10.39"/>
                    <measurement group_id="O3" value="89.12" spread="9.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30min_QT Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="385.11" spread="25.55"/>
                    <measurement group_id="O2" value="385.27" spread="29.72"/>
                    <measurement group_id="O3" value="385.53" spread="42.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30min_RR Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" spread="0.12"/>
                    <measurement group_id="O2" value="0.81" spread="0.16"/>
                    <measurement group_id="O3" value="0.81" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End_PR Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165.94" spread="38.63"/>
                    <measurement group_id="O2" value="149.43" spread="11.33"/>
                    <measurement group_id="O3" value="165.63" spread="25.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End_QRS Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.67" spread="13.43"/>
                    <measurement group_id="O2" value="87.50" spread="9.63"/>
                    <measurement group_id="O3" value="89.00" spread="10.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End_QT Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="371.94" spread="41.97"/>
                    <measurement group_id="O2" value="377.00" spread="25.33"/>
                    <measurement group_id="O3" value="391.13" spread="43.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End_RR Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79" spread="0.12"/>
                    <measurement group_id="O2" value="0.80" spread="0.11"/>
                    <measurement group_id="O3" value="0.82" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>ECG Measures at All Time Points by Group</title>
        <description>Infusion 2 (Day 14) - ECG measures at all time points by group</description>
        <time_frame>Day 14 - Baseline (pre-infusion), During Infusion (@30 min), Post-Infusion (@60min)</time_frame>
        <population>All subjects receiving a complete or partial Phase 2 infusion</population>
        <group_list>
          <group group_id="O1">
            <title>Drug - Drug</title>
            <description>Phase 1 - intravenous sodium Nitroprusside (Drug) Phase 2 - intravenous sodium Nitroprusside (Drug)
Subjects will receive i.v. sodium nitroprusside (0.5 μg/kg/min for 4 hours) at Day 0 (Phase 1) and Day 14 (Phase 2)</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Drug</title>
            <description>Phase 1 - intravenous dextrose (Placebo) Phase 2 - intravenous sodium Nitroprusside (Drug)
Subjects will receive i.v. placebo (intravenous dextrose) at Day 0 (Phase 1) and i.v. sodium nitroprusside (0.5 μg/kg/min for 4 hours) at Day 14 (Phase 2)</description>
          </group>
          <group group_id="O3">
            <title>Placebo - Placebo</title>
            <description>Phase 1 - intravenous dextrose (Placebo) Phase 2 - intravenous dextrose (Placebo)
Subjects will receive i.v. placebo (intravenous dextrose) at Day 0 (Phase 1) and again at Day 14 (Phase 2).</description>
          </group>
        </group_list>
        <measure>
          <title>ECG Measures at All Time Points by Group</title>
          <description>Infusion 2 (Day 14) - ECG measures at all time points by group</description>
          <population>All subjects receiving a complete or partial Phase 2 infusion</population>
          <units>mm/sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline_PR Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155.47" spread="23.46"/>
                    <measurement group_id="O2" value="149.46" spread="15.61"/>
                    <measurement group_id="O3" value="167.61" spread="20.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline_QRS Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.82" spread="11.29"/>
                    <measurement group_id="O2" value="86.46" spread="10.05"/>
                    <measurement group_id="O3" value="91.33" spread="12.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline_QT Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="379.35" spread="29.59"/>
                    <measurement group_id="O2" value="385.69" spread="35.84"/>
                    <measurement group_id="O3" value="387.33" spread="38.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline_RR Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80" spread="0.17"/>
                    <measurement group_id="O2" value="0.86" spread="0.16"/>
                    <measurement group_id="O3" value="0.84" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30min_PR Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156.18" spread="21.95"/>
                    <measurement group_id="O2" value="146.69" spread="14.85"/>
                    <measurement group_id="O3" value="172.00" spread="19.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30min_QRS Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.18" spread="11.95"/>
                    <measurement group_id="O2" value="87.00" spread="7.98"/>
                    <measurement group_id="O3" value="88.44" spread="10.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30min_QT Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="389.18" spread="25.33"/>
                    <measurement group_id="O2" value="360.08" spread="46.52"/>
                    <measurement group_id="O3" value="380.44" spread="33.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30min_RR Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" spread="0.11"/>
                    <measurement group_id="O2" value="0.77" spread="0.18"/>
                    <measurement group_id="O3" value="0.82" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End_PR Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160.41" spread="26.48"/>
                    <measurement group_id="O2" value="153.55" spread="19.87"/>
                    <measurement group_id="O3" value="165.63" spread="21.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End_QRS Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.41" spread="9.90"/>
                    <measurement group_id="O2" value="86.64" spread="9.90"/>
                    <measurement group_id="O3" value="89.50" spread="9.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End_QT Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="387.06" spread="38.89"/>
                    <measurement group_id="O2" value="384.91" spread="29.89"/>
                    <measurement group_id="O3" value="383.25" spread="31.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End_RR Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80" spread="0.16"/>
                    <measurement group_id="O2" value="0.86" spread="0.11"/>
                    <measurement group_id="O3" value="0.81" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Incidence of Treatment-Emergent Adverse Events (TEAEs)</title>
        <description>Incidence of Treatment-Emergent Adverse Events (TEAE) by Treatment Group. A treatment emergent adverse event (TEAE) is an AE that either began following initiation of study treatment or was present prior to the initiation of the treatment, but increased in frequency or severity following initiation treatment, regardless of causality.</description>
        <time_frame>The period of observation for collection of treatment-emergent adverse events extends from Day 0 treatment through the final visit at Day 28.</time_frame>
        <population>Number of Treatment-Emergent Adverse Events (TEAEs) in Each Treatment Group</population>
        <group_list>
          <group group_id="O1">
            <title>Drug - Drug</title>
            <description>Phase 1 - intravenous sodium nitroprusside Phase 2 - intravenous sodium nitroprusside
sodium nitroprusside: intravenous</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Drug</title>
            <description>Phase 1 - intravenous dextrose Phase 2 - intravenous sodium nitroprusside
sodium nitroprusside: intravenous</description>
          </group>
          <group group_id="O3">
            <title>Placebo - Placebo</title>
            <description>Phase 1 - intravenous dextrose Phase 2 - intravenous dextrose
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Treatment-Emergent Adverse Events (TEAEs)</title>
          <description>Incidence of Treatment-Emergent Adverse Events (TEAE) by Treatment Group. A treatment emergent adverse event (TEAE) is an AE that either began following initiation of study treatment or was present prior to the initiation of the treatment, but increased in frequency or severity following initiation treatment, regardless of causality.</description>
          <population>Number of Treatment-Emergent Adverse Events (TEAEs) in Each Treatment Group</population>
          <units># of TEAEs</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Subject Withdrawals Due to Treatment-Emergent Adverse Events (TEAEs)</title>
        <description>Incidence of Treatment-Emergent Adverse Events (TEAE) by Treatment Group. A treatment emergent adverse event (TEAE) is an AE that either began following initiation of study treatment or was present prior to the initiation of the treatment, but increased in frequency or severity following initiation treatment, regardless of causality.</description>
        <time_frame>The period of observation extends from Day 0 treatment through the final visit at Day 28</time_frame>
        <population>All subjects withdrawn from the study due to TEAEs</population>
        <group_list>
          <group group_id="O1">
            <title>Drug - Drug</title>
            <description>Phase 1 - intravenous sodium Nitroprusside (SNP) Phase 2 - intravenous sodium Nitroprusside (SNP)
Subjects will receive i.v. sodium nitroprusside (0.5 μg/kg/min for 4 hours) at Day 0 and Day 14</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Drug</title>
            <description>Phase 1 - intravenous dextrose (Placebo) Phase 2 - intravenous sodium Nitroprusside (SNP)
Subjects will receive i.v. placebo (intravenous dextrose) at Day 0 and i.v. sodium nitroprusside (0.5 μg/kg/min for 4 hours) at Day 14</description>
          </group>
          <group group_id="O3">
            <title>Placebo - Placebo</title>
            <description>Phase 1 - intravenous dextrose (Placebo) Phase 2 - intravenous dextrose (Placebo)
Subjects will receive i.v. placebo (intravenous dextrose) at Day 0 and again at Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subject Withdrawals Due to Treatment-Emergent Adverse Events (TEAEs)</title>
          <description>Incidence of Treatment-Emergent Adverse Events (TEAE) by Treatment Group. A treatment emergent adverse event (TEAE) is an AE that either began following initiation of study treatment or was present prior to the initiation of the treatment, but increased in frequency or severity following initiation treatment, regardless of causality.</description>
          <population>All subjects withdrawn from the study due to TEAEs</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Systematic Assessment for Treatment Emergent Effects-Systematic Inquiry (SAFTEE-SI) - Percent of Participants Reporting Experiencing Symptoms at &quot;Moderate&quot; or &quot;Severe&quot; Level for the 10 Most Frequently Reported Symptoms Post Randomization</title>
        <description>The Systematic Assessment for Treatment Emergent Effects-Systematic Inquiry (SAFTEE-SI): This is a self-rated 77-item questionnaire organized into 13 body areas assessing possible adverse events during the course of the trial.</description>
        <time_frame>Baseline (Day - 1), Follow-Up = reported at any assessment thereafter, including 7 hours after Infusions #1 and #2, Baseline 2 (Day 13) and final follow-up, including early termination visits.</time_frame>
        <population>Includes all subjects with SAFTEE data</population>
        <group_list>
          <group group_id="O1">
            <title>Drug - Drug</title>
            <description>Phase 1 - intravenous sodium nitroprusside Phase 2 - intravenous sodium nitroprusside
sodium nitroprusside: intravenous</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Drug</title>
            <description>Phase 1 - intravenous dextrose Phase 2 - intravenous sodium nitroprusside
sodium nitroprusside: intravenous</description>
          </group>
          <group group_id="O3">
            <title>Placebo - Placebo</title>
            <description>Phase 1 - intravenous dextrose Phase 2 - intravenous dextrose
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Systematic Assessment for Treatment Emergent Effects-Systematic Inquiry (SAFTEE-SI) - Percent of Participants Reporting Experiencing Symptoms at &quot;Moderate&quot; or &quot;Severe&quot; Level for the 10 Most Frequently Reported Symptoms Post Randomization</title>
          <description>The Systematic Assessment for Treatment Emergent Effects-Systematic Inquiry (SAFTEE-SI): This is a self-rated 77-item questionnaire organized into 13 body areas assessing possible adverse events during the course of the trial.</description>
          <population>Includes all subjects with SAFTEE data</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>10. Baseline - Hearing or seeing things</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2"/>
                    <measurement group_id="O2" value="25.0"/>
                    <measurement group_id="O3" value="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10. Follow-Up - Hearing or seeing things</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="31.3"/>
                    <measurement group_id="O3" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3. Baseline - Feeling drowsy or sleepy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3. Follow-Up - Feeling drowsy or sleepy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2"/>
                    <measurement group_id="O2" value="25.0"/>
                    <measurement group_id="O3" value="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8. Baseline - Trouble concentrating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="6.3"/>
                    <measurement group_id="O3" value="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8. Follow-Up - Trouble concentrating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1"/>
                    <measurement group_id="O2" value="18.8"/>
                    <measurement group_id="O3" value="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7. Baseline - Poor memory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1"/>
                    <measurement group_id="O2" value="6.3"/>
                    <measurement group_id="O3" value="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7. Follow-Up - Poor memory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                    <measurement group_id="O2" value="25.0"/>
                    <measurement group_id="O3" value="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1. Baseline - Trouble Sleeping</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="6.3"/>
                    <measurement group_id="O3" value="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1. Follow-Up - Trouble Sleeping</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1"/>
                    <measurement group_id="O2" value="12.5"/>
                    <measurement group_id="O3" value="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4. Baseline - Feeling nervous or hyper</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                    <measurement group_id="O2" value="18.8"/>
                    <measurement group_id="O3" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4. Follow-Up - Feeling nervous or hyper</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                    <measurement group_id="O2" value="18.8"/>
                    <measurement group_id="O3" value="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18. Baseline - Dry mouth</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                    <measurement group_id="O2" value="12.5"/>
                    <measurement group_id="O3" value="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18. Follow-Up - Dry mouth</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                    <measurement group_id="O2" value="25.0"/>
                    <measurement group_id="O3" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>34. Baseline - Frequent need to urinate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="6.3"/>
                    <measurement group_id="O3" value="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>34. Follow-Up - Frequent need to urinate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                    <measurement group_id="O2" value="18.8"/>
                    <measurement group_id="O3" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17. Baseline - Stuffy nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                    <measurement group_id="O2" value="6.3"/>
                    <measurement group_id="O3" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17. Follow-Up - Stuffy nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                    <measurement group_id="O2" value="18.8"/>
                    <measurement group_id="O3" value="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>52. Baseline - Hot flashes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="6.3"/>
                    <measurement group_id="O3" value="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>52. Follow-Up - Hot flashes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1"/>
                    <measurement group_id="O2" value="6.3"/>
                    <measurement group_id="O3" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The period of observation for collection of adverse events extends from the time the subject gave informed consent until the final visit at Day 28.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Drug - Drug</title>
          <description>Phase 1 - intravenous sodium nitroprusside Phase 2 - intravenous sodium nitroprusside
sodium nitroprusside: intravenous</description>
        </group>
        <group group_id="E2">
          <title>Placebo - Drug</title>
          <description>Phase 1 - intravenous dextrose Phase 2 - intravenous sodium nitroprusside
sodium nitroprusside: intravenous</description>
        </group>
        <group group_id="E3">
          <title>Placebo - Placebo</title>
          <description>Phase 1 - intravenous dextrose Phase 2 - intravenous dextrose
Placebo: Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Abnormal ECG</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Irregular Heart Activity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Increased Heart Rate</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred Vision</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Increased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Lightheadedness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pelvic Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Heat Exhaustion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated ALT Levels</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>White Blood Cell Decrease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Tingling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Feeling Nervous or Hyperactive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Libido</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Low O2 Saturation Rate</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hot Flashes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Maurizio Fava, MD</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-724-2513</phone>
      <email>MFAVA@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

